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Abstract
For cancer cells, metabolic reprogramming is important for balancing energy, maintaining
redox homeostasis, and synthesizing biosynthetic precursors. Thus, targeting metabolism
has become a valid anticancer strategy to pursue. Among others, respiratory complex I (CI)
has been identified as a valid target. In this context, a genetic ablation of mitochondrial CI
enzyme in colorectals (HCT) and osteosarcomas (143B) was associated with the lack of HIF-1α
stabilization and subsequent inability to adapt to hypoxic environment, suggesting this may
contribute to the anti-tumorigenic effect of CI deficiency. However, most recent data imply that,
despite the lack of HIF-1α , the progression of CI-deficient tumors seems to be supported by
components of tumor microenvironment (TME), in particular tumor associated macrophages
(TAMs). Thus, the aim of this thesis was (i) to prove that the lack of HIF-1α stabilization and
subsequent inability to adapt to hypoxic environment is a generalized phenomenon in murine,
human cancers and in an orthotopic system and may contribute to the anti-tumorigenic effect
of CI deficiency; (ii) to prove that the CI-deficient tumors activate macrophages to progress
despite HIF-1α destabilization; (iii) to identify common targetable factors responsible for
macrophage recruitment among the CI deficient 143B and HCT models. By introducing a non
degradable form of HIF-1α (HIF-TM) in CI deficient models, we demonstrated that HIF-TM
rescued their tumorigenic potential, mature vasculature and vessel size. Moreover, in 143B
CI deficient model, lack of HIF-1 activity correlated with macrophage migration inhibitory
factor (MIF) downregulation and macrophage abundance. This indicated that the disruption of
HIF-1-MIF axis leading to vasculature remodeling and TAM recruitment is one of the adaptive
mechanisms activated by the CI defective 143B tumors. However, this mechanism may not be
generalized to the epithelial HCT model. Large-scale omics approach on CI deficient and CI
competent 143B and HCT xenografts derived supernatants identified nine common metabolites
secreted specifically from both the CI deficient models, allowing to hypothesize a potential
cytokine-like function of these metabolites in attracting TAMs.
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1.1 HALLMARKS OF CANCER AND TUMOR MICROEN-
VIRONMENT
Cancer is defined as an abnormal division of cells that have escaped the normal growth and
survival control mechanisms, disabled by genetic mutations in their oncogenes or tumor
suppressor genes (TSG). These dense complexities of cancer enabling them to transform from
a normal cell to malignant cell, was organized into six major “hallmarks” by Hanahan and
Weinberg in 2000, (Hanahan and Weinberg, 2000) namely: sustaining proliferative signalling,
evading cell death, evading growth suppressors, enabling replicative immortality, inducing
angiogenesis, and activating tissue invasion and metastasis. A decade later, the same authors
added four new hallmarks: reprogramming energy metabolism, evading immune response,
genome instability and mutation, and tumor-promoting inflammation (Hanahan and Weinberg,
2011) (Fig. 1.1). These hallmarks have proven to be a solid foundation for understanding
the common traits acquired by cancer and rationalizes their evolution from a normal cell into
malignancy and therefore in guiding their treatment.
1.1.1 CELL POPULATIONS OF THE TUMOR MICROENVIRONMENT
The tumor mass, apart from cancer cells, contains a range of infiltrating and resident cells
(immune cells and stroma), extracellular matrix proteins and secreted factors cumulatively
known as the tumor microenvironment (TME). The cell populations of TME include endothe-
lial stromal cells, immune cells such, stromal fibroblasts, non-cellular extracellular matrix
components such as collagen, fibronectin, hyaluron, laminin, etc; and several cell types of
innate and adaptive immune cells (Fig. 1.2) (Bhagban et al., 2020). The progression of a
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Fig. 1.1 Illustration of the ten hallmarks of cancer as proposed by Hanahan and Weinberg.
(Adapted from Hanahan and Weinberg, 2011).
tumor is substantially influenced by the interactions of cancer cells with their environment,
eventually determining their fate. The selection of progressing cancer cells, among other, is
influenced by the cellular and non-cellular components of TME, often resulting in activation
of signalling networks that promotes using non-malignant cells and their activity for tumor
advantage. Tumors attract immunosuppressive (protumorigenic) myeloid-derived suppressor
cells (MDSCs) and Foxp3-expressing regulatory T-cells (Tregs), while subduing immunity
promoting cytotoxicity of CD4+ and CD8+ T effectors and natural killer (NK) cells (Chen
and Mellman, 2017). Indeed non-malignant cells of TME are considered to facilitate tumori-
genesis at all stages of cancer growth and metastasis, which is why TME has become the
focus of intense research to reveal new avenues for the treatment of cancer. Depending on
the tumor type and stage, the degree to which TME influences cancer cell progression varies.
For example, macrophages found in tumors (TAMs) may release inhibitory cytokines such
as IL-10, prostaglandins or reactive oxygen species (ROS) and are re-programmed to inhibit
lymphocyte functions (Mantovani et al., 2003; Martinez et al., 2008). MDSCs may facilitate
tumor development and suppress immune cell activity by copiously developing an enzyme
involved in the metabolism of l-arginine, arginase 1, which synergizes with iNOS to increase
the production of superoxide and NO, blunting lymphocyte responses (Ochoa et al, 2007).
Stimulated cancer associated fibroblasts (CAFs) secrete stromal cell-derived factor 1 (SDF-1)
to promote angiogenesis by recruiting circulating endothelial progenitor cells (EPCs) into the
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tumor mass (Orimo and Weinberg, 2006). Recent evidence shows that inflammatory monocytes
are recruited by tumor cells and host organ-derived chemokine chemokine (C-C motif) ligand 2
(CCL2) that differentiate into macrophages and promote efficient seeding and development
of tumor cell metastases in distant metastatic lung sites (Qian et al., 2011). It has been exten-
sively shown that signals promoting protumorigenic TME functions are cancer cell-derived.
For example, tumors may produce several factors, including IL-10, VEGF, GM-CSF, which
facilitate the aggregation and maturation of MDSC and Tregs and block dendritic cells (DC) as
well as CD4+ and CD8+T effector functions. Furthermore, tumor cell-secreted Interleukin-4
(IL-4) facilitates macrophage polarization from pro-inflammatory (antitumorigenic) M1 to
proangiogenic M2 TAMs (Vitale et al., 2019).
Fig. 1.2 The cells of tumor microenvironment: A schematic image of the components of the
tumour microenvironment. Most developed solid cancers are normally surrounded by a large
number of stromal cells and immune cells that infiltrate.
1.1.2 HYPOXIA AS THE KEY CONDITION IN TUMOR MILIEU
Apart from harbouring different cell types, TME is characterized by a particular milieu, which
due to uncontrolled fast proliferation often results in hypoxia and acidification (Petrova et
al., 2018). The salient characteristic of certain tumors is that they exist in a low oxygen
atmosphere (hypoxia) ranging from 0 to 2% O2 because the rate of proliferation of tumor
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cells always exceeds the rate of development of new blood vessels (angiogenesis). In a
normal as well as in a cancerous cell, adaptation to hypoxia is governed by hypoxia inducible
factor 1 (HIF-1), a pleiotropic transcription factor that leads to transcription of genes such
as vascular endothelial growth factor (VEGF) that promotes endothelial cell formation, and
glucose transporters (Glut1) which is responsible for glucose uptake and lactate dehydrogenase-
A (LDHA) which regulates the conversion of pyruvate to lactate. HIF-1 are also involved in
proliferation of cells, survival, and development of tumors by controlling growth promoters,
oncogenes and glycolytic pathways (Masoud and Li, 2015). Moreover, HIF-1α helps cells to
monitor the decreased intracellular pH that occurs as a result of increased anaerobic glycolysis
and the subsequent production of lactic acid (Weidemann and Johnson, 2008). Therefore
HIF-1 mediates a transition from oxidative to glycolytic metabolism under hypoxic conditions.
Hydroxylation by the prolyl hydroxylase PHD2 of a particular proline residue in HIF-1α under
well-oxygenated conditions triggers the von Hippel-Lindau (VHL) protein, which recruits an
ubiquitin ligase that targets HIF-1α for proteasomal degradation (Kaelin and Ratcliffe, 2008).
In addition, HIF-1 (FIH-1) inhibiting agent represses the action of HIF-1α transactivation
using O2 and alpha-ketoglutarate as substrates by hydroxylation an asparaginyl residue, thus
preventing the interaction of HIF-1α with the p300 protein coactivator (Lando et al., 2002).
Hypoxia, on the other hand, inhibits PHDs and stabilizes HIF-1α , which then translocates
into the nucleus and dimerizes with constitutively expressed HIF-1β , forming an active HIF-1
complex and inducing its gene transcription to facilitate glycolytic metabolism, angiogenesis
and survival (Ruas and Poellinger, 2005) (Fig. 1.3). The correlation between increased HIF-1
levels and aggressive tumor growth and poor patient prognosis is supported by a large number
of studies. HIF-1, which causes increase in the metabolic genes involved in glycolytic flux,
coordinates the metabolic adaptation to hypoxia (Chen et al, 2014; Baba et al, 2010; Semenza,
2013).
1.2 CANCER METABOLISM
Due to their unrestrained proliferation, tumor cells have remarkably different metabolism
as compared to their tissue of origin (Ward and Thomson, 2012). Considering the excess
amount of nutrients utilized and excreted by the proliferating cancer cells, they undergo
metabolic reprogramming that provide them with continuous supply of energy even during
nutrient starvation period, allowing them to survive under severe selective pressure. Growing
tumors need to generate vast amount of lipids, nucleotides, proteins and energy to maintain
their growth. These anabolic processes are supported by the increase uptake of glucose and
upregulation of glycolysis (Vander Heiden et al, 2009). Otto Heinrich Warburg pioneered
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Fig. 1.3 A schematic image of the mechanisms by which transcription factor HIF-1α regulates
the levels of genes involved in aerobic glycolysis, angiogenesis, erythropoiesis and pH regula-
tion in hypoxic tumors. p- HIF-1α is hydroxylated to proline residue in normoxia and targeted
for proteasome degradation (PHD- prolyl-hydroxylase; VHL- von Hippel-lindau factor, HRE-
hypoxia responsive elements (Adapted from Supuran, 2017).
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investigations of cancer cell metabolism when he described a process by which the cancer
cells survived by relying on aerobic glycolysis rather than oxidative phosphorylation even
in the presence of oxygen called the “Warburg effect” (Warburg, 1956). He suggested the
upregulation of glycolysis is most likely due to dysfunctional mitochondria (Warburg, 1956).
However, this theory has been negated over the past decade as it has been demonstrated that
the upregulation of glycolysis in cancer cells is governed by oncogenic signalling (Gaude
and Frezza, 2014). Moreover, it is now generally accepted that cancer cells require both
glycolysis and mitochondrial respiration to survive (Koppenol et al, 2011). The molecular
mechanisms involved in the metabolic reprogramming in cancer are convoluted, engaging
extensive remodelling of multiple signalling pathways like the HIF-1α , c-Myc, Ras and
phosphatidylinositol-3-OH kinase (PI3K), mTOR (mammalian target of rapamycin) and AMP-
activated protein kinase (AMPK) (Semenza, 2010; Shaw and Cantley, 2006; Shackelford and
Shaw, 2009). During the process of glycolysis, glucose is converted into lactate to generate
two ATP molecules. In cancer cells about 60% of ATP production is by glycolysis (Busk M
et al, 2008). Cancer cells preferential dependence on glycolysis stems from the fact that this
pathway is essential for the biosynthesis of lipids, proteins, nucleic acids, production of lactate
and to maintain the NAD+/NADH redox balance. Presence of hypoxic core in tumors further
accentuates the necessity of glycolysis (Lunt SY, Vander Heiden MG, 2011). The discerning
ability of cancer cells to adapt or bypass certain metabolic process to fulfil their energy needs
has been a topic of great interest to many researchers with several anti-cancer therapies being
proposed to target cancer metabolism.
1.2.1 MITOCHONDRIA
Mitochondria often referred to as the powerhouse of cell are subcellular organelles inherited
maternally and are essential for bioenergetics, biosynthesis, and cell signalling. Mitochondria
are double lipid layered membrane organelle divided into the intermembrane space (IMS),
outer mitochondrial membrane (OMM), inner mitochondrial membrane (IMM) with cristae
to provide large surface area for ATP production, and the mitochondrial matrix (Fig. 1.4).
Mitochondria have their own genetic system with many copies of a circular DNA (mtDNA),
which is composed, of 16.569 base pairs. Only 13 proteins are encoded by the mtDNA, whereas
most of the oxidative phosphorylation (OXPHOS) system is encoded by the nucleus and then
translocated into mitochondria by multicomponent import machinery (Calvo and Mootha,
2010).
The most well known metabolic reaction taking place in mitochondria is OXPHOS, which
results in energy production in the form of ATP. The trans-membrane electrochemical gradient
that drives ATP synthesis is generated by the high pH of the mitochondrial matrix created by
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Electron transport chain (ETC). The final electron acceptor is oxygen at the end of ETC, and this
eventually forms water, together with ATP (Fig. 1.4). The participating ETC protein complexes
include NADH dehydrogenase complex I (CI), Succinate dehydrogenase (CII), Cytochrome
bc1 complex (CIII), and Cytochrome c oxidase (CIV). This generates a proton concentration
gradient that is used by ATP synthase or complex V (CV), to fuel the production of ATP
energy carrier molecule (Taylor and Turnbull, 2005). In addition to metabolic alterations,
through their direct involvement in apoptosis and the production of reactive oxygen species
(ROS), mitochondria contribute to tumorigenesis. The latter can promote oxidative stress,
increase the instability of the nuclear genome, and influence signalling pathways involved in
cell proliferation, differentiation, and hypoxia adaptation (Storz, 2005). In addition, mutations
in mtDNA typically end up impacting protein translation or structure provided the highly
compressed organization of mtDNA, which is mainly coding. Moreover, the key sites of ROS
development are respiratory CI and CIII and have been designated as causative for the high
mutational rate of mtDNA, especially in the context of somatic mutation generation (Leone
et al., 2018). In a number of human cancers, alterations in mtDNA have also been identified.
For example, subsets of hepatocellular carcinomas and prostate cancers were associated with a
mutation in the D-loop region of CI (Nomoto et al., 2002).
Fig. 1.4 The mitochondrial structure description. In the inner mitochondrial membrane, the ETC
is embedded. The movement of the electrons through the ETC and the subsequent generation
of adenosine triphosphate (ATP) is shown. Via CI or CII, electrons (e-) from reduced substrates
join the ETC and are then transferred through CIII and CIV where oxygen (O2) has been
reduced to create water (H2O) (solid black lines). The inner membrane potential is decreased
by protons that escape back through the mitochondrial inner membrane and into the matrix
(dashed red line). Q = coenzyme Q; C = cytochrome c. (Adapted from Mcewen et al., 2011).
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1.2.2 MITOCHONDRIAL METABOLIC ALTERATIONS IN CANCER
Although cancer cells show upregulated glycolysis, under the condition of limited nutrients,
i.e, glucose deprivation, they increase the mitochondrial respiration to survive (Smolková et
al., 2010) A central mechanism for the synthesis of sugars, lipids and amino acids is the TCA
cycle (Fig. 1.5). It is typically viewed in a naive view of a cyclic mitochondrial pathway that
continuously oxidizes the acetyl moiety of acetyl-coenzyme A to CO2, forming nicotinamide
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), whose electrons
power the ATP generating mitochondrial respiratory chain (Cardaci and Ciriolo, 2012). Inter-
estingly, we now know that a typical cellular reaction to disrupted mitochondrial metabolism
is glutamine-dependent reductive carboxylation. This mechanism acts as the predominant
metabolic strategy to generate lipids for the growth of cancer cells and can be acutely induced
through ETC inhibition. Reductive carboxylation is induced by a disruption caused by ETC
impairment in the redox ratio of the mitochondria, reducing the NAD+/NADH ratio and making
the TCA’s oxidative role less effective (Mullen et al., 2011; Gaude et al., 2018; Fendt et al.,
2013). TCA is also fuelled by process called glutaminolysis, which involves catabolizing
glutamine by glutaminase (GLS) to produce ATP. In order to use a significant fraction of TCA
cycle intermediates as precursors for biosynthetic pathways, glutamine metabolism enables
cells to retain an adequate anaplerotic flux (DeBerardinis et al, 2008). In addition, many
cancers overexpress fatty acid synthase (FASN), a key biosynthetic enzyme involved in lipo-
genesis to synthesize fatty acids de novo, to provide lipids for membrane formation, energy
production via β -oxidation and lipid modification of proteins to fulfil the requirement of the
rapidly proliferating cells (Ogino et al., 2008). Therefore even with impaired mitochondrial
mechanism, cancer cells implement different energy acquisition pathways to progress. Cellular
metabolism reprogramming occurs both directly and indirectly as a result of oncogenic muta-
tions. Mutations in the metabolic genes such as FH, SDH, IDH that leads to the accumulation of
certain metabolites like succinate, fumarate and (R)-2-hydroxyglutarate (HG), act as oncogenic
signalling molecules in variety of human tumors (Gaude and Frezza, 2014). IDH mutations are
gain-of-function mutations at odds with SDH and FH loss of function mutations and confer on
the enzyme the capacity to generate the oncometabolite D-2-hydroxyglutarate (D-2HG). These
oncometabolites share the ability to inhibit alpha-ketoglutarate (α-KG)-dependent enzymes
that regulate epigenetic gene expression, such as histone lysine demethylases of the Jumonji
domain (JMJ) and ten-eleven translocation (TET) dioxygenases, resulting in the expression of
a potentially oncogenic transcriptional program associated with a terminal differentiation block
(Xiao et al., 2012; Xu et al., 2011; Saha et al., 2014). Interestingly, succinate and fumarate
accumulation is not only caused by primary mitochondrial defects, but may also be derived
from oncogenic protein signalling such as KRAS (Masgras et al., 2017). Mutations in all the
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above mentioned enzymes of the TCA cycle compel cells to rely on a truncated TCA cycle that
results in the stabilization of the subunits of HIF-1α , even during presence of oxygen resulting
in a pseudo-hypoxic phenotype.
Fig. 1.5 Representative image of glycolysis and TCA cycle. PPP= Pentose phosphate pathway.
1.2.3 TARGETING CANCER METABOLISM
Through selective toxicity against proliferating cells, the earliest anticancer drugs focused
on targeting cancer metabolism. Sidney Farber in 1947, found that in children with acute
lymphoblastic leukemia, aminopterin (folate analog) could induce disease remission. This early
therapeutic success of antifolates has since led to development of drugs called antimetabo-
lites. Small molecules resembling nucleotide metabolites are the antimetabolites that also
inhibit the function of enzymes involved in nucleotide base synthesis. For example, the 5-
fluorouracil(5-FU) pyrimidine analog, a synthetic uracil analog, inhibits thymidylate synthase,
limiting thymidine nucleotide supply for DNA synthesis. Today, 5-FU and the associated 5-FU-
prodrug capecitabine remain frequently used in chemotherapy and are an effective medication
for gastrointestinal cancer (Heidelberger et al., 1957; Wagner et al., 2007). The purine and
pyrimidine antimetabolites, some of the earliest anticancer drugs, specifically attack essen-
tial metabolic pathways needed for proliferation. These include the drugs gemcitabine and
cytarabine, which are integrated into DNA, resulting in DNA polymerase inhibition (Parker,
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2009). Lactate has been identified in the microenvironment of almost every solid tumor type.
There has been emerging evidence that argues lactate plays a fundamental role in regulat-
ing different signalling pathways to promote tumor progression. MCTs inhibitors such as
α-cyano-4-hydroxy-cinnamic acid (ACCA, 4CIN, CHCA) and techniques like silencing MCTs
by siRNA have already been utilized as promising cancer therapeutics (Matthew, 2010; Lee,
2016). Pharmacological agents, which inhibit IDH1 and IDH2 mutants, is developed and tested
for an anti-tumor efficacy. AGI-5198, which targets mutant IDH1, for instance reduces the rate
of intratumoral D-2HG, inducing expression of genes implicated in glial cells differentiation
and inhibits development in IDH1-mutant human glioma cells (Rohle et al., 2013). A particular
mutant IDH2 inhibitor, AG-2211 (enasidenib) provides survival advantage in a mouse model of
IDH2-AML mutation (Quivoron et al., 2014; Yen et al., 2017). Present glutaminolysis targeting
efforts have mainly centered on inhibiting glutaminase. In cancer trials in patients, one potent
glutaminase inhibitor, CB-839, is currently being tested. (William et al., 2014). Targeting
FASN has been shown to decrease tubulin palmitoylation and interrupt the organisation of
microtubules, inhibiting development in tumor cells (Heuer et al., 2017). While arginine is
not critical in normal tissue, some solid cancers do not produce argininosuccinate synthetase
(ASS), and are instead auxotrophic to arginine and are thus susceptible to its depletion (Riess
et al., 2018). Several lines of evidence indicate that autophagy mediated by PI3K / Akt /
mTOR pathway may be a viable target to prevent drug resistance and increase tumour cell
chemosensitivity (Xu et al., 2020). While several inhibitors have been developed (Fig. 1.5) and
are currently in clinical trials, owing to their effects on mitochondrial reprogramming in cell
bioenergetics and cell trafficking, they have not shown exciting results in patients (Caino et al.,
2015)
1.2.4 TARGETING MITOCHONDRIAL COMPLEX I (CI) AND ITS
CONSEQUENCES ON CANCER PROGRESSION
CI is the ETC ’s rate limiting and first enzyme. It is crucial for the production of cellular energy,
supplying about 40 percent of the proton motive force required for ATP synthesis (Sazanov,
2014). It oxidizes NADH to NAD+ and donates the released electrons to the coenzyme Q10
(CoQ10, also known as ubiquinone) electron carrier, linking this mechanism to the translocation
from the mitochondrial matrix to the intermembrane space of four protons (Sazanov, 2014). CI
is made up of 45 distinct subunits in humans, seven of which (the ND subunits) are encoded by
mtDNA and the others by the nuclear (nDNA) genome (Fig. 1.7). CI contributes to the proton-
motive force (PMF) needed by the FoF1-ATP-synthase (CV) to drive different mitochondrial
functions, including ATP production (Koopman et al., 2010). The ETC and CV together














































Fig. 1.6 Targeting metabolic reprogramming in cancer. In a fast proliferating cancer cell,
glycolysis and TCA cycle intermediates are used for macromolecule biosynthesis (proteins,
lipids and nucelotides). Energy is produced by both glycolysis and oxidative phosphorylation.
Glutamine may serve for TCA cycle intermediates replenishment. Atypical accumulation of
metabolites such as D-2HG may promote epigenetic remodelling. mTORC1 regulates several
transcription factors to promote glycolysis and macromolecule biosynthesis. These metabolic
reactions have been recognized as valid targets for cancer treatment and some of the current
metabolic anti-cancer strategies are indicated in red.
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constitute the system of OXPHOS. To perform the catalytic function of CI, only 14 evolutionary
conserved CI core subunits are needed, seven coded by mtDNA (ND1, ND2, ND3, ND4,
ND4L, ND5, ND6) and seven coded by nDNA (NDUFV1, NDUFV2, NDUFS1, NDUFS2,
NDUFS3, NDUFS7, NDUFS8) (Roestenberg et al., 2011) In many pathological disorders,
such as neurodegenerative diseases (Rodenberg, 2016; Marin et al., 2013), diabetes (Elango
et al., 2014), and cancer (Kurelac et al., 2013, Iommarini et al., 2013), defects in nuclear and
mitochondrial genes encoding CI subunits are a contributing factor. These findings are however
contentious with respect to cancer. The differential effects of CI on tumor progression depend
upon the severity of its impairment (Iommarini et al., 2013). Although CI gene mutations
has shown to encourage prostate, thyroid, renal, lung, colorectal, breast and head and neck
tumors progression (Allergra et al., 2006;Akouchekian et al., 2011; Horton et al, 1996; Kim
et al., 2016, Su et al., 2016; Yu et al., 2015), multiple studies by our group show opposite
effects of CI mutations on tumor progression (Iommarini et al., 2013; Calabrese et al., 2013).
This emphasizes the role of CI as an “oncojanus” (Gasparre et al., 2011). The action of CI is
necessary to retain the cellular NAD+ pool and the NAD+/NADH ratio required to support
the action of MDH2, oxidoreductase-dependent NAD+/NADH ratio and aspartate generation.
Consequently, inhibition of CI affects the equilibrium of NAD+/NADH, causing a reduction in
electron acceptors. This in turn limits aspartate synthesis, which is a precursor of the synthesis
of purine and pyrimidine required for cell proliferation for the biosynthesis of nucleic acids
and macromolecules (Birsoy et al., 2015; Sullivan et al., 2015). In addition, inhibition of
CI, which is required for the maintenance of the NAD+/NADH ratio for the induction of
hypoxia adaptive mechanisms through HIF-1α , results in the accumulation of NADH, which
in turn causes the inhibition of α-ketoglutarate (α-KG) dehydrogenase, thereby increasing the
α-ketoglutarate/succinate (αKG/Suc) ratio, which favors the activity of the prolyl-hydroxylases
in charge of the degradation of HIF-1α , resulting in tumor growth arrest (Gasparre et al., 2013;
Selak et al., 2005; Calabrese et al., 2013) Targeting CI influences tumorigenesis and cancer
progression via various pathways. Modulating CI activity affects the development of ROS, the
rate of oxygen intake, the levels and use of NADH, the generation of ATP, the use of metabolic
pathways and the quantity of signalling metabolites, as explained in the review by Vatrient el al.,
2015. Several small molecule CI inhibitors are now being used as anti-cancer strategies, such
as carboxyamidotriazole (CAI) BAY 87-2243, fenofibrate, metformin, phenoformin, caulerpin,
canagliflozin, and AG311 compounds. The mechanism of action of these inhibitors is triggered
by ATP depletion, an increase in the development of ROS that inhibits the signalling of AMP-
activated protein kinase (AMPK), angiogenesis and also by HIF-1α destabilisation (Ju et al.,
2016; Agani et al., 2002; Liu et al., 2009; Cheong et al., 2011; Villani et al., 2016; Bastian
et al., 2017). This is also in agreement with the study by Iommarini et al., 2014, where the
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authors showed that CI-defective cancer cells display an increase cellular AMP/ATP ratio and
AMPK activation under metabolic stress conditions (Iommarini et al., 2014). Furthermore,
in low nutrient conditions, CI dysfunction was found to increases cellular AMP/ATP ratio,
eventually leading to activation of AMPK, by slowing down biosynthetic reactions (Faubert
et al., 2013). Thus, CI enzyme can be used as a target for the development of new anticancer
therapies, considering its important role in regulating metabolism, hypoxic adaptation and cell
proliferation.
Fig. 1.7 Overview of the CI modules. In it pictured are the N-module (colored in green),
iron–sulfur (Fe-S) clusters (orange spheres), Q module (in gold), Pp-proximal in violet and
Pd-distal in salmon. (Giachin et al., 2016).
1.3 METABOLIC CROSS TALK BETWEEN CANCER
CELLS AND THEIR TUMOR MICROENVIRONMENT
Recent years have seen an outburst of reports revealing that tumor metabolism highly depends
on the relationship between malignant cells and the cell populations of TME. As a consequence
of metabolite shortage in TME, a series of metabolic relationships are developed between cancer
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cells and their neighboring non-malignant cell populations, which apart from available nutrient
competition may incorporate mutually beneficial interactions or parasitosis-like phenomena.
1.3.1 METABOLIC COMPETITION AND COOPERATION
Apart from nutrients and waste, poor tissue coverage and irregular tumor vasculature limit the
exchange of gases and create hypoxic areas. The hypoxic reaction contributes to increased
tumor glycolytic activity and excessive deposition of lactate. The lactate build-up acidifies
the TME, which affects how the immune system detects and manages a neoplastic lesion.
In addition, nutrient restriction in the TME provides a framework for immune, stromal, and
cancer cells where they are in constant competition for nutrients essential for biosynthesis,
bioenergetic, and effector activities (Fig. 1.8). Immune cells tend to be less suited to nutritional
rivalry, and this is a crucial anti-tumor immunity control mechanism. For example, cancer
cells deplete vital nutrients, such as glucose from the TME and thereby avoid cytotoxic T
cell activation. (Chang et al., 2015). As the amino acid serine is an important metabolite
for the expansion of effector T-cells, local serine depletion by cancer cells is also likely to
inhibit penetration and activation of immune cells (Ma et al., 2017). Although immune cells
are vying for nutrients with cancer cells, CAFs demonstrate a symbiotic relationship with
cancers. When in contact with pancreatic cancer cells, pancreatic CAFs, originated from
activated pancreatic stellate cells (PSCs), excrete alanine. Pancreatic cancer cells then capture
this alanine and use it to drive macromolecular biosynthesis. In addition, alanine secretion
from PSCs requires autophagy activation, which is induced by cancer cells. Collectively, these
findings reveal a metabolic crosstalk pathway between PSCs and cancer cells, where pancreatic
cancer cells transmit signals to trigger autophagy in PSCs, which promotes access to alanine in
the pancreatic TME to promote tumor growth (Sousa et al., 2016).
1.3.2 METABOLIC BY-PRODUCTS AS SIGNALLING MOLECULES
IN TME
To create a hostile metabolic environment for immune cells, cancer cells tend to secrete
excess metabolites. Metabolites also act as signalling molecules, in addition to their role in
biosynthesis, through autonomous and non-autonomous mechanisms. In the latter case, in
neighboring cells, metabolite shared within the TME regulates signal transduction and gene
expression. In this context, lactate has been acknowledged as a bioenergetics substrate rather
than a metabolic waste (Garcia et al., 2016). The most well-known effect of lactate and acidosis
on TME regards its promotion of angiogenesis, either by directly acting on endothelial cells
(Vegran et al., 2011) or indirectly by instigating the secretion of VEGF (Fukumura et al.,
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Fig. 1.8 The consequences of cancer cell metabolic reprogramming on the non-malignant
populations of TME. Full and dashed lines indicate respectively stimulation and inhibition.
Wavy line represents metabolite exchange between cancer associated fibroblasts and cancer
cells.
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2001) from tumor cells and TAMs (Colegio et al., 2014). Apart from its role in promoting
angiogenesis, lactate was also associated with suppression of the anti tumor immune response
by inducing an increase in the numbers of myeloid-derived suppressor cells (MDSCs) and
therefore inhibiting function of natural Killer (NK) cells. Moreover, lactate also perturbs the
metabolism of the T cells and protects the tumor cells from the cytotoxic T-cell targeting
(Husain et al., 2013; Brand et al., 2016; Fischer et al., 2007). Similarly, lactate also facilitates
the induction of M2 macrophage phenotype (Mu et al., 2018; Chen, 2017; Colegio et al.,
2014) (Fig. 1.8). More recently, cancer-secreted succinate, in addition to stabilizing HIF-1α
expression, induced macrophage polarization and increased macrophage migration and cancer
metastasis (Wu et al., 2020). The other ways by which the metabolic activity of cancer cell
alters the tumor microenvironment and promotes them to support tumor development is by the
release of kynurenine (Kyn), another metabolic waste, eventually blunting the immune cell
function. IDO and Kyn, the byproduct of tryptophan degradation, can induce FoxP3 expression
and the generation of Treg cells and can blunt the generation of TH17 helper cells in cancer
cells (Romani, 2008; Sharma et al., 2009). These studies provide further evidence that tumor
metabolism and immunity are tightly interconnected.
1.3.3 TARGETING MITOCHONDRIAL COMPLEX I (CI) AND ITS
CONSEQUENCES ON TME
Despite the involvement of all components of immunity in a host, it is a daunting clinical task
to establish how components of TME, tumor metabolism and immune checkpoints all play
a part in the effective survival and dissemination of tumors. However, non-specific toxicity
poses a significant challenge in the use of metabolic inhibitors for anti-cancer therapy, as all
host cells that also contain TME use the same survival metabolic pathways. In this regard, the
use of metabolic drug can also cause unintentional adverse effects on the TME (Table 1). For
example, it has been shown that mTOR inhibitors have pleiotropic effects on multiple immune
cells and endothelial cells. An active area of research is the role of mTOR in controlling the
differentiation and function of CD8 + T cells, as well as the effect of inhibition on these cells.
While some studies indicate that mTOR inhibition can promote the function of memory T, other
results indicate that T cells lacking mTOR differentiate into Tregs (Conciatori et al., 2018).
CI inhibition by BAY87-2243 on H460 lung cancer xenografts in nude mice caused HIF-1α
deactivation and reduced HIF-1mediated gene expression (Ellinghaus et al., 2013). Metformin
and Phenformin targeted both breast cancer cells and white adipose tissue endothelial progenitor
cells in vivo and in vitro, resulting in profound effects on angiogenesis of breast cancer and
their metastatic development, possibly due to additive effects on both tumor and TME cells
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(Orecchioni et al., 2015). Metformin also reduced production of angiogenesis related proteins
like VEGF, Angiogenin, MMP-9 in Human MDA-MB-436 breast cancer (Wang et al., 2015).
In addition, AG311 CI inhibitor destabilized HIF-1α in hypoxia and reduced expression of
HIF-1 target genes in breast cancers (Bastein et al., 2017). Metformin treatment also increased
T-cell infiltration into murine melanoma tumors in vivo (Pereira et al., 2018). Of note, although
a growing body of epidemiological and clinical studies report metformin as a viable anti-cancer
drug, the subject is still controversial. Although there is a bulk of literature reporting the
effect of metformin on the TME, there is a lack of evidence regarding the effects of other
anti-metabolic drugs on TME, pressing the importance of considering this parameter for future
studies.
Table 1.1 A list of studies reporting TME-related effects of metformin and/or complex inhibition















C57BL/6 increased capillary density, upregulated
VEGF and promoted angiogenesis in Is-
chemic Tissue in vivo
C2C12 in vitro increased VEGF mRNA expression in
C2C12 myotubes




increased VEGFA production in vitro and
in vivo, increased microvascular density (re-
duced Ki-67)




increased VEGFA production in cancer cells
indirect effect H460 lung cancer
xenografts in nude
mice
BAY 87-2243 complex I inhibitor caused
HIF-1α deactivation and reduced in HIF1-
mediated gene expression
indirect effect HCT116p53-/- reduced HIF1, VEGF and CAIX in vitro and
in vivo in xenografts
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indirect effect Human MDA-MB-
436 breast cancer in
vitro
metformin and phenphormin reduced produc-
tion of angiogenesis-related proteins (IGFBP-
2, PDGFAA, VEGF, Angiogenin, MMP-9
and endostatin)
in vivo vessels FVB mice injected
with murine MMTV-
Erbb2 BC cells
reduced microvascular density and endothe-
lial cell component in the tumors
in vivo vessels matrigel sponge as-
say in C57Bl6 mice
reduced angiogenesis
HUVEC in vitro reduced endothelial cell proliferation, migra-
tion and network formation
indirect effect HepG2, Huh7 hepa-
tocellular carcinoma
cell lines
HIF1, CAIX and Glut1 downregulation in
vitro and in vivo in xenografts
HUVEC co-culture with 4T1
or MDA-MB-453
breast cancer cells
reduced proangiogenic capacity of met-
formin pre-treated cancer cells
in vivo vessels
(tumor)
4T1 tumors in Balb/c
mice
reduced vessel leakiness and smaller vessel
size/diameter in tumors
in vitro MDA-MB-435 and
MDA-MB-231 in
vitro
AG311 CI inhibitor destabilized HIF-1α in
hypoxia and reduced expression of HIF1-
target genes
indirect effect GBC-SD xenograft
model
HIF1 and VEGF downregulation in GBC
cells





genetic knock-out of CI in cancer cells pre-
vented HIF-1α stabilization, reduced vessel















overexpression of mitochondrial uncoupling
proteins induced high-energy nutrient produc-
tion in fibroblasts, which may support cancer





metformin reduced CAF-mediated support
of cancer cell progression
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tumors in which MRC5 were primed with
metformin increased sensitivity to cisplatin
patient-derived
CAFs
ovarian cancer reduced IL-6 secretion
in vivo CAFs pancreatic adenocar-
cinoma 6606PDA or-
thotopic in C57BL/6











suppressed proclonogenic CAF effect on can-
cer cells





genetic knock-out of CI in cancer cells asso-








RAW.264.7 in vitro LPS stimula-
tion
inhibited NF-KB pathway (translocation of





in vitro LPS stimula-
tion








decreased number of CD68+ cells, decreased
LPS-induced cytokine secretion (IL-6, IL-8,
IL-1b, TNF-α and IL-10)
RAW.264.7 in vitro induced expression of M2 markers (Arg1, IL-






upregulated proinflammatory factors (IL-6,
IL-1b, TNF-α , MCP-1)
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in vivo TAMs pancreatic cancer:
PAN02 (in C57BL/6)
and AK4.4 (in FVB)
decreased number of TAMs, decreased Arg1




in vitro LPS stimula-
tion
metformin and rotenone decreased IL-1b,
TNF-α and increased IL-10 expression
THP-1 in vitro PMA stimu-
lation
reduced CD206 receptor expression, and
MRC1 and dectin mRNA
RAW.264.7 in vitro IL-13 stimu-
lation
reduced M2 signature (Mrc1, Pparγ , Ccl24,
Ccr2, Mgl2, Retnla, and Arg1)
in vivo TAMs Lewis lung carci-
noma (in C57BL/6)
no difference in TAM numbers, but reduced
CD206 receptor expression
THP-1 in vitro PMA stimu-
lation
reduced monocyte to macrophage differenti-












inhibited cancer cell-mediated macrophage
migration









calvaria model of os-
teolysis
increased CD206 expression, decreased TNF-




obese C57BL/6 mice decreased serum levels of the proinflamma-
tory cytokines IL-6 and TNF-α , lowered the
expression of the M1 macrophage markers
CD11c and MCP-1 in adipose tissue
RAW.264.7 in vitro palmitate
stimulation





decreased the ratio of M1/M2 macrophages
(increased CD206 expression)
in vivo TAMs 4T1 breast cancer in
BALB/c
increased CD68+ in tumors, higher iNOS,
lower Arg1 expression
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RAW.264.7 in vitro IL-13 stimu-
lation
reduced Arg1 expression, no effect on iNOS





higher number of F4/80, higher number of
Ly6C- monocytes, no difference in CD206
expression
in vivo TAMs genetic knock-out of CI in cancer cells in-
duced higher TAM abundance, higher num-
ber of Ly6C- monocytes, no difference in





in vivo TILs RLmale1 tumors in
Balb/c mice








(triple cytokine secretion:IL-2, IFNg,
TNF-α)
in vivo TILs murine melanoma
cells (B16F10) in
C57BL/6










CD4+Foxp3+IL10+T cells (IL10 negatively







repression of tumor cell OCR and an increase
in T cell OCR; tumor infiltrating T cells have
an increase in the number of the activated T
cells;
in vivo CTL 4T1 breast cancer in
BALB/c
metformin decreases PD-L1 levels in cancer
cells, increased of the CD8+ CTL population;





lower levels of IL22 in the tumors by decreas-
ing the numbers of both Th1 cells and Th17
cell
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metformin decreases in the Treg/CD4+ T cell
ratio in tumors
1.3.4 TARGETING MITOCHONDRIAL COMPLEX I (CI) AND ITS
CONSEQUENCES ON MACROPHAGES
In the tumour microenvironment of solid tumours, macrophages are one of the most abundant
immune cells and their existence coincides with decreased survival in most cancers (Noy and
Pollard, 2014). At all stages of tumour development, macrophages are present and promote
angiogenesis, tumour cell invasion, and intravasation at the primary site. In this context, the
consequence of TAMs in metabolic therapy has been explained. In obese / diabetic persons
with pancreatic cancer, metformin alleviates the fibro-inflammatory microenvironment by re-
programming pancreatic stellate cells and TAMs, which coincides with decreased development
of the disease (Incio et al., 2015). Although not in tumor settings, metformin atherosclerosis
therapy inhibits monocyte-to-macrophage differentiation through inhibition of STAT3 activa-
tion mediated by AMPK (Vasamsetti et al., 2015). Metformin prevented the development of
prostate cancer in transgenic adenocarcinoma of the mouse prostate (TRAMP) by targeting
TAM infiltration (Liu et al., 2018). in vitro studies using TAMs-conditioned medium and a
multi-cancer co-culture system demonstrated an inhibitory effect of metformin by encouraging
M2-polarized RAW264.7 macrophages on endothelial sprouting and tumor cell proliferation
(Wang et al., 2018). The findings of our group regarding the effect of CI deficiency showed
contribution of TAM infiltrations as an adaptive mechanism acquired by the CI deficient os-
teosarcomas and colorectal cancers (Kurelac et al., 2019). This instigated us to dissect the
mechanism of TAM recruitment in these metabolically constrained models of CI deficient
tumors, which is the focus of this thesis.
Chapter 2
AIMS
Disruption of the mitochondrial CI by genetic or pharmacological targeting has been envisaged
as plausible anti-cancer therapy. The metabolic disruption following CI disassembly prompts
HIF-1α destabilization that has been attributed as one of the primary mechanisms triggered in
these tumors. However, it has never been demonstrated whether HIF-1 inactivation is the cause
of lower tumorigenic potential of CI deficient tumors.
(1a) Thus, the first aim was to prove that the lack of HIF-1α stabilization and subsequent
inability to adapt to hypoxic environment contributes to the anti-tumorigenic effect of CI
deficiency.
(1b) To prove that this phenomenon is generalized in murine setting and that it also occurs
in an orthotopic cancer model that closely mimic human condition.
It is important to note that even though maintaining low-proliferative phenotype, CI-
deficient tumors still persist when left to grow overtime. Most recent data imply that the
progression of CI-deficient tumors seems to be supported by components of TME, in particular
TAMs.
(2) Thus, the second aim was to determine the factors leading to macrophage abundance
in CI deficient tumors, with the overall goal to identify a specific druggable target that could




3.1 CELL LINES MAINTENANCE
Osteosarcoma 143B Tk- cells, HCT116 cells and B16F10 murine melanoma cells were cul-
tivated in Dulbecco’s modified Eagle medium (DMEM) High Glucose (Euroclone), supple-
mented with 10 % fetal bovine serum (Euroclone), L-glutamine (2mM, Euroclone), penicillin /
streptomycin (Euroclone) and uridine (50µg / ml, Sigma-Aldrich), in a humidified atmospheric
incubator at 5% CO2 and 37 ° C , respectively. On 15 passages, cells were replaced by a
fresh batch (approximately every two months) and mycoplasma testing was performed before
disposal and after each thawing. Hypoxia experiments with 1% of O2 concentration, were
carried out within the Invivo2 300 (Baker Ruskinn) chamber, set up at 5% CO2 and 37 ° C.
3.2 GENERATION OF TM-HIF-1α
The HIF-1α cDNA wild-type sequence was cloned in the pGEM (Promega # A1360) vector
and mutagenesis was performed using the Quickchange Site-Guided Mutagenesis Kit (Agilent
# 200518) to induce mutations at the PHD hydroxylation sites following previously mentioned
indications as directed by the manufacturer (Tal et al., 2008). The HIF-TM ensures constitutive
activation of the protein, even in normoxia. In specific, three mutations were introduced in
the HIF-1α sequence, to replace the prolyl hydroxylase (PHD)-targeted prolines and Factor
Inhibiting HIF (FIH)-targeted asparagine with residues that can not be hydroxylated (P402A,
P564 G, and N803A) (Fig. 3.1). The triple mutant HIF-1α was then transferred into the
retroviral vector of pMSCV-Puro (Clontech # PT3303-5). Following the phxA transduction
protocol mentioned above, the empty vector and the vector comprising TM-HIF-1α were
then used to transduce 143B and HCT116 cells. Cells carrying the vectors were picked with
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puromycin 2 µgmL-1 (Sigma # P8833) and grown in medium supplemented with puromycin 1
µ4gmL-1. To classify the clones with the highest levels of TM-HIF-1α protein in normoxia,
clonal selection was performed and a pool of 20 clones was made.
Fig. 3.1 Representation of the three point mutations of the HIF-1α ensuring a non degradable
and constitutive activation of the protein, even in normoxia.
3.3 GENOME EDITING FOR GENERATION OF NDUFS3
KNOCK-OUT
The generation of the NDUFS3 KO using zing finger nucleases for the 143B osteosarcomas and
HCT colorectals was carried out as described previously (Kurelac et al., 2019). CRISPR/Cas9
system was used to introduce a frameshift mutation in Ndufs3 gene for the murine melanoma
B16F10 cell lines . In detail, Cas9 protein (Invitrogen#A36497) was transfected by following
manufacturers instructions using Lipofectamine™ CRISPRMAX™ Cas9 Transfection Reagent
(Invitrogen #CMAX00015) together with synthetic RNA guides designed by Deskgen and
purchased from Synthego. Exon 1 targeting guide ACATGGCGGCGGCTGCAGCC with PAM
sequence AGG was used to create clone E6(1) and Exon 3 targeting guide TTGTGGGTCA-
CATCACTCCG with PAM sequence GGG was used to create G4(2). Cells were split and
harvested 48 hours after transfection and DNA was extracted using Mammalian Genomic DNA
Miniprep Kit (Sigma-Aldrich #G1N350). Non-homologous repair efficiency was evaluated by
Sanger Sequencing using KAPA2G Taq polymerase (Kapa Biosystems #KK5601) and Big Dye
protocol (Life Technologies #4337451). In particular, for Exon 1 58°C annealing temperature
was used for the PCR reaction, with primers forward TGCGTCTTCTTCTCTTCGGC and
reverse CAACGAAAGGCCCCAGCTAA. For Exon 3 61°C annealing temperature was used
for the PCR reaction, with primers forward CTGTAACTCCAGTCTCAGGGA and reverse
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CACACTGCAGGGATCACTTG. Manual clonal selection was performed in order to identify
the cells with frameshift Ndufs3 mutations. DNA extraction from 96-well plates was performed
using 8 µl of Lysis Solution (Sigma-Aldrich #L3289) and 80 µl of Neutralization Buffer
(Sigma-Aldrich #N9784) per sample, following manufacturer’s instructions.
3.4 MITOCHONDRIA ISOLATION
Membrane fractions enriched with mitochondrial proteins (mitoplasts) were extracted using
digitonin (final 50 µg / mL concentration) from cell pellets (10×106 cells). Digitonin, which
destabilizes and solubilizes the cell membranes, binds to membrane cholesterol. Unlike the
outer membrane, the inner membrane is almost devoid of cholesterol, so digitonin solubilizes
the cell membranes, with the exception of the inner membrane, which can be separated while
remaining intact. In short, cells were centrifuged and pellets suspended with cold PBS at a
concentration of 10×106 cells / mL, and incubated on ice for 1 minute after the addition of
digitonin. Cold Phosphate-buffered saline (PBS) was then applied to dilute the suspension
volume to 2.5-fold, thus disrupting cell permeabilization. Treatment with digitonin was
repeated until at least 90% of the cells were permeabilized, as detected by Trypan blue cell
permeabilization under the microscope. At 13000 rpm for 15 minutes at 4 ° C, the cells were
then centrifuged and the pellet was stored at -80 ° C. Proteins were then quantified using the
bradford assay.
3.5 CN-PAGE
Complex I was separated by Clear Native PAGE (CN-PAGE)(Wittig et al., 2006). Cells were
resuspended in PBS at 107 cells / ml, permeabilized with digitonin at 50 µg / ml, centrifuged
for 10 minutes at 13000 rpm and the mitochondrial pellet was stored at -80 ° C. The next day,
the mitochondrial buffer (750 mM 6-aminocaproic acid, ACA; 50 mM BisTris, pH 7.0) was
used to resuspend the pellet, the proteins were quantified and DDM (n-Dodecyl β -D-maltoside)
added 2.5 times the amount of protein. Subsequently samples were incubated for 10 minutes in
ice and then centrifuged for 15 minutes at 4 °C at 13000 rpm. We then retrieved the supernatant
containing the mitochondrial proteins and quantified the proteins. In the CN-Sample Buffer
(0.1% Red Ponceaux and 50 percent Glycerol), the supernatant collected was diluted. 50 µg of
mitochondrial protein samples were loaded onto a native gel made of a polyacrylamide gradient
of 4% to 12%, made with gradient construction machinery and a Delta-Pump (Peristaltic Pump).
Running gels were prepared to add 25 mM Imidazole, 0.5 M ACA, pH 7, 0.02 percent APS
and 0.02 percent TEMED to the existing acrylamide concentrations; 10 percent glycerol was
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applied to the higher concentration gradient. There was 4 percent acrylamide in the stacking
gel. For CN-PAGE (50 mM Tricine, 7.5 mM Imidazole, 0.02 percent DDM, 0.05 percent
NaDOC pH 7), the anode buffer and cathode buffer were used. At 80V, electrophoresis was
performed. Gels were immersed in a solution containing 2 mM Tris-HCl, 0.5 percent 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 0.02 percent NADH for
15 minutes after electrophoresis at room temperature, in the dark. Because of the reduction of
MTT to tetrazolium salts by NADH oxidation by CI, the CI emerged as a black band.
3.6 SDS-PAGE AND WESTERN BLOT ANALYSIS
In RIPA buffer [TrisHCl pH7.4 (50mM), NaCl (150mM), SDS (1%), Triton (1%), EDTA pH7.6
(1mM)] supplemented with protease inhibitors (Roche) and quantified by Lowry protein assay
(Biorad), whole lysates of cultured cells and freshly snapped frozen xenograft samples were
prepared. Samples were isolated by SDS-PAGE and moved to the nitrocellulose membrane
using the Turbopack method (Biorad) The membranes were blocked at 37 °C for 30 minutes
and incubated with primary antibodies using the following dilutions / conditions: anti-NDUFS3
(AbCam #177471) 1:1000/1-h at room temperature (RT); anti-HIF-1α (GeneTex #GTX127309)
1:2000/1-h at RT; anti-Vinculin (Sigma-Aldrich #V9131) 1:10,000/1-h at RT; anti-MIF (AbCam
#175189) 1:5000/1-h at RT; anti-ACTB (Santa Cruz #SC-1615) 1:500/1-h at RT; anti-p53
(Santa Cruz #SC-126) 1:1000/1-h at RT. TBS-Tween [0.1 percent Tween 20 (Sigma-Aldrich
# P9416) in Tris Buffered Saline] was washed for 4× 5 minutes and secondary antibody
incubation (Jackson ImmunoResearch Labs # 111035144 and # 111035146), diluted 1:20,000
in TBS-Tween, was conducted at RT for 30 minutes. The membrane development was carried
out with Clarification Western ECL Substrate (Bio-Rad # 1705061) and ChemiDoc XRS+
(Bio-Rad) exposure. The Western Breeze method (Life Technology # WB7106) was used for
anti-NDUFS3 antibodies for secondary antibodies and developing solutions, following the
manufacturer’s instructions.
3.7 CELL VIABILITY
The Sulforhodamine B (SRB) assay (Sigma-Aldrich) and cell counting after staining with
trypan Blue (Sigma-Aldrich) measured cell viability. Cells were seeded in a complete medium
onto 24-well plates (7.5×103cells / well for B16F10). For additional conditions, cells were
washed twice in PBS 24 hours after seeding and incubated in the specified media i.e., either
low glucose (5mM), galactose (5mM) or high glucose (25mM). Briefly, cells were fixed with
50 percent trichloroacetic acid for 1 hour at 4 ° C at the end of incubation time, washed 5 times
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with H2O and finally dried at room temperature for 1 hour. Cells were then stained at room
temperature with SRB 0.4% diluted in 1% acetic acid for 1 hour, washed 4 times with 1%
acetic acid, and disrupted at pH 9.8 with 10 mM Tris-HCl. SRB absorbance was detected at a
wavelength of 560 nm by the Tecan plate reader.
3.8 RNA EXTRACTIONS, qRT-PCR
The expression of quantitative real-time PCR gene was evaluated based on minimal knowledge
for the publication of guidance for quantitative real-time PCR (qRT-PCR) experiments (Bustin
et al., 2009). In particular, RNA was extracted for cell lines using Trizol (Life Technologies
# 15596018) and for snap-frozen xenograft samples using the Mammalian Genomic DNA
Miniprep Kit (Sigma-Aldrich # RTN70). Applied Biosystems # 4368814 (High Capacity cDNA
ReverseTranscription Kit) was used to prepare cDNA with random hexamers beginning from
300 ng of RNA. Using Primer3 program (Skaletsky and Rozen, 2000), Primer sequences were
designed. Using IDT OligoAnalyzertool (http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/),
the presence of 3 ’intra/inter primer homology was ruled out. Primer sequences used for
SLC2A1, VEGF, LDHA and TBP were previously designed and sequences mentioned in
publication from Calabrese et al. for (Calabrese et al., 2013). MIF primers: F: AGAAC-
CGCTCCTACAGCAAG, R: GAGTTGTTCCCAGCCCACATT . P21 primers: F: GGCA-
GACCAGCATGGACAGATT, R: GCGGATTAGGGCTTCCTCCT. GoTaq qPCR Master Mix
(Promega # A6002) was used to execute the PCR reaction and operate the 7500 Fast Real-Time
PCR Method (Applied Biosystems), under the following conditions: 95 ° C for 5 minutes; 95 °
C for 45 intervals for 15 seconds and 60 ° C for 45 seconds. The measurements were carried
out using the [ct(control)-ct(experiment)] 2-∆∆CT calculus, where the control was determined
as the average ct value obtained from control samples. The normalization was done using TBP.
Using the ∆ct values [ct(gene of interest)-ct(reference gene)] for each biological replication in
a population and applying student T-test, the statistical significance was determined (Yuan et
al., 2006).
3.9 P53 TRANSFECTION
For the P53 experiments (Fig. 3.2), X-tremeGENE™ HP DNA Transfection Reagent (XTGHP-
RO Roche) was used to tranfect P53 Wild type (WT) or P54 Mutated (Mut) plasmid according
to the manufacturer’s instructions for time period of 24 hours. The cell lines were then subjected
to hypoxia incubation in 1% O2 hypoxic chamber or in 21% O2 conditions in an incubator. The
32 EXPERIMENTAL PROCEDURES
RNA was extracted using Trizol (Life Technologies #15596018) for cell lines. qRT-PCR was




























Fig. 3.2 Graphical representation of P53 transfection method in the HCT-/- cells.
3.10 IN VIVO TUMOR GROWTH
Nu / nu mice (CD-1 ® Nude Mouse Crl: CD1- Foxn1n) were purchased from Charles River
Laboratories for in vivo tests. Animal testing and analysis has been complied with all applicable
ethical legislation. The animals were treated at the university of Bologna in compliance
with institutional standards and regulations. The Italian Ministry of Health (authorization
code 437/2018-PR) authorised the ethical report. Female mice aged five to six weeks were
subcutaneously injected with a 100 µL suspension of of 5 × 106 cells in serum-free medium
and matrigel (Corning # 356234) on the right flank of the animal. Using a sliding caliper,
the xenograft scale was calculated twice a week according to the formula: volume = width *
height * length/2 and the tumor growth was followed accordingly. Mice were either sacrificed
concurrently when 10% of animal weight was achieved by the first xenograft, or consecutively
when each animal achieved xenograft volume corresponding to 10% of animal weight or met
the requirements for termination.
3.11 ESTABLISHING PSEUDO-ORTHOTOPIC OSTEOSAR-
COMAS
The pseudoorthotopic model was established by Ander Abberateghi from The Francis Crick
Institute, London, UK. Briefly, in sterile conditions, all pre-surgical operations have been
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carried out. Gelfoam gelatin sponges (2 cm × 6 cm × 7 mm) (Pfizer, Kalamazoo, MI, USA)
were cut into 24 parts, washed in sterile PBS with 70% ethanol, rehydrated and put in a 24-well
plate. HMSC cells (5×105 in 50 ul) were injected with a syringe (29 G) and left in a 37 C
incubator for 4 hours for attachment. Cultural media was introduced and for 7 days the cells
were left to expand. Cells of osteosarcoma (105 in 30 ul) were inserted into the scaffold on
day 8 and left to attach before adding new culture media. A 15 mL tube and 8 uL of Bone
Morphogenic Protein 2 (BMP-2) (Noricum, Tres Cantos, Spain) were assigned to each scaffold.
Then 30 uL of human plasma thrombin (Sigma, Dorset, UK) (reconstituted by 2% CaCl2 at
20 U / mL) and 20 uL of human plasma fibrinogen (Sigma) (reconstituted by 4 mg/100 mL
PBS) were incorporated. In cell culture conditions, solidification was permitted for 30 minutes
before progressing to in vivo implantation. In aseptic conditions, surgery was performed. At
The Francis Crick Institute Biological Research Facility (London, UK), five to six-week old
female Rag1-/- FVB / n mice were used. For each implantation of the scaffold, a 0.5 cm vertical
incision was made on each side of the animal 1 cm away from the spine. A pocket under
the skin in the incision, down the side of the animal, was made with forceps. A scaffold was
inserted to ensure that it was positioned deep within the bag, and then incisions were dried and
glued (Fig. 3.3).
Fig. 3.3 Schematic diagram representing the generation of the pseudo-orthotopic osteosarcomas
in Rag1-/- FVB/n mice.
3.12 CYTOKINE ARRAY
Xenograft-derived cell cultures were generated by a 10-day cultivation of liberase-digested
tissue in basal conditions. Supernatant (0.5 mL) was taken 2 days after medium renewal
and analyzed with human Proteome Profiler Array kit (R&D Systems, ARY005B) following
manufacturer’s instructions.
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3.13 IMMUNOFLUORESCENT (IF) AND IMMUNOHIS-
TOCHEMICAL (IHC) STAINING
3.13.1 IHC
Following standard protocols, the samples were fixed in formalin for 24 hours before transfer-
ring them into 70% ethanol. The tissue was then fixed in paraffin and cut using the microtome .
Tissue parts (4 µm) in xylene were deparaffinized, rehydrated in absolute ethanol, followed
by heat-induced buffer epitope retrieval (TE-T with 10 mM Tris pH 8.0, 1 mM EDTA, 0.05
percent Tween 20 or trypsin-based antigen retrieval with 0.05%trypsin in 0.1mM Calcium
chloride solution, pH 7.8) for 40 min at 95 ° C and 20 min at RT. Sections are then washed with
phosphate-buffered saline containing 0.5 percent Tween 20 (PBS-T pH 7.4). Primary antibodies
were dissolved in antibody diluent with background reducing components (Dako # S3022)
and incubated for 30 min or 1 hour at RT. Blocking, secondary staining and development of
antibodies with DAB substrate were conducted using the Envision Detection System (Dako
# K4007 and # K4011) as directed by the manufacturer. Hematoxylin was used as a counter
stain. The following primary antibodies were used: rabbit monoclonal anti-NDUFS3 (1:200,
Abcam #177471); rabbit polyclonal anti-HIF-1α (1:350, Sigma-Aldrich #HPA001275) and
rat monoclonal F4/80 (1:100, eBiosciences #14-4801). Neutrophil marker 2b10 antibody was
developed in house at The Francis Crick Institute.
3.13.2 IF
Following standard protocols, the samples were fixed in formalin for 24 hours before transfer-
ring them into 70% ethanol. The tissue was then fixed in paraffin and cut using the microtome .
Tissue parts (4 µm) in xylene were deparaffinized, rehydrated in absolute ethanol, followed
by citrate antigen retrieval (10mM sodium citrate, pH 6) at 95 ° C for 15 min and at RT
for 20 min. Blocking with goat serum (Abcam # 156046) for 10 min at RT and incubation
with secondary antibodies to Alexa Fluor (488-goat anti-mouse diluted 1:500 and 555-goat
anti-rat diluted 1:350) for 40 min at RT was carried out. Rat anti-Endomucin (1:200, Santa
Cruz # SC-65495) and mouse anti-SMA (1:750, Dako # M0851) were the following primary
antibodies used. Vectashield Antifade Mounting Medium with DAPI (Vector Labs, # H-1200)
was used to mount slides. The size of the vessel was measured by calculating 30 endomucin
positive cells per tumor longer in diameter and avoiding fibroblast infiltrated areas . At 20X
magnification per tumor, fibroblasts (SMA+Endo-) and immature vessels (Endo+SMA-) were
counted in five fields of view. Pictures were taken with the Zeiss Axio Scope Z1 scanner using
the software ZEN (Carl Zeiss Microscopy GmbH, Germany). Trypsin-based antigen retrieval
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(0.05 percent trypsin in 0.1mM calcium chloride solution, pH 7.8) was conducted for 30 min
at 37 ° C for macrophage staining with anti-F4/80 and biotinylated goat secondary anti-rat
antibody (Sigma-Aldrich # A9037) was used along with VECTASTAIN ABC-HRP Kit (Vector
Laboratories # PK-4005). Macrophage was counted at five fields of view per tumor (F4/80 +)
at 20X magnification.
3.14 FLOW CYTOMETRY ANALYSIS
The cytometry data were obtained by Ivana Kurelac at the The Francis Crick Institute, London,
UK. Briefly, immediately after the mice sacrifice, xenograft samples ( 50 mm3) were digested
in HBSS for 40 min at 37 ° C with Liberase TL (Sigma # 5401020001), Liberase TM (Sigma #
5401135001) and DNaseI (Sigma # DN25) and passed through a 100 µm strainer. Red Blood
Cell Lysis Buffer (Sigma # 11814389001) hypotonic lysis was carried out and the residual cells
were washed with MACS buffer (2 mM EDTA, 0.5 percent BSA in PBS), blocked with FcR
Blocking Reagent (Miltenyi # 130-092-575) and incubated with pre-labeled antibody panels.
In parallel, for fluorescence minus one (FMO) reading, spleen, lung and a control tumor tissue
were digested together and stained, which was considered when setting the gating strategy.
The panel used was: anti-F4/80-APC780 (clone BM8, eBioscience #47-4801-80), anti-CD45-
PE (clone 30-F11, eBioscience #12-0451-82), anti-Ly6G-APC (clone 1A8, BD Bioscience
#560599), anti-CD11b-ef450 (clone M1/70, eBioscience #48-0112-82), anti-CD11c-PeCy7
(clone N418, Biolegend #117317), and anti-CD49b-FITC (clone 30-F11, Biolegend #108905)
at 1:100 dilutions while anti-CD45 was used at 1:300 dilution. Dead cells were stained with
DAPI. The samples were run on LSRFortessa Cell Analyzer (BD Biosciences). BD FACSDIVA
Software (BD Bioscience) and Flow Jo (Tree Star Inc.) software were used for the analysis of
the results.
3.15 METABOLOMICS
The metabolomics analysis was carried out in University of Cambridge in Dr Christian Frezza’s
lab (MRC cancer unit). The conditioned media for the LC-MS were extracted according to
the protocol from Frezza’s lab. The ex vivo cultures were seeded in 6 well plates and left to
attach for 24 hours after which the media was replaced by a fresh media. After a period of 24
hours, the conditioned media was collected and processed (Fig. 3.4). 5uM d8-Valine was used
as the internal standard. LC-MS analysis was performed using a Q Exactive mass spectrometer
(Thermo Fisher Scientific) joined to a U3000 UHPLC system Dionex. The LC system was
fitted with a Sequant ZIC-pHILIC column (150 mm × 2.1 mm) and guard column (20 mm
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× 2.1 mm) from Merck Millipore (Germany). The mobile phase was composed of 20 mM
ammonium carbonate and 0.1% ammonium hydroxide in water (solvent A), and acetonitrile
(solvent B). The mass spectrometer was operated in full MS and polarity switching mode.
The acquired spectra (an ion chromatograms) were analyzed using XCalibur Quan Browser
software. To generate the heatmap, the pathway analysis using KEGG metabolic pathways as
the backend knowledge base and the metabolite set enrichment analysis, metaboanlayst was
used (https://www.metaboanalyst.ca/MetaboAnalyst/faces/home.xhtml)
Fig. 3.4 Experimental setting of the extraction of the conditioned media from the ex vivo
cultures for LC-MS analysis.
3.16 PROTEOMICS
The proteomics was carried out in Max Planck Institute for Molecular Genetics in the lab
of Prof David Meierhofer. The ex vivo cultures were seeded at concentration of 1x106 cells
in triplicates on a 10cm dish and were left to attach overnight. The next day, cells were
washed stringently and gently, twice with Hanks balanced salt solution with calcium and
magnesium. 6ml of media without FCS and phenol red was added. The media was collected
after 24 hours in a low protein binding tube and centrifuged for 10 min at 2000xg at 4°C.
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5.5ml of the media was then transferred into a new low protein binding tube and 750ul of
TCA (final concentration 12%) and precipitated on ice for 2 hours. After 2 hours, the sample
were centrifuged at 3500x g for 10 min at 4°C. The supernatant was discarded and 2 ml of
pre-cooled tertrahydrofurane (THF) was added. The pellet was vortexed until it was dislodged
from bottom of tube and dissolved completely. The wash with THF was repeated again and
the samples were collected and processed by nanoflow reverse phase liquid chromatography
(Dionex Ultimate 3000, Thermo Scientific, Waltham, MA) coupled online to a Q-Exactive
HF Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA) as previously described
(Kürschner et al., 2017).
3.17 STATISTICAL ANALYSIS
GraphPad Prism version 6 (GraphPad Software Inc., San Diego, CA, USA) was used to
perform statistical tests and create bar plots and graphs. Unless stated otherwise, a two-tailed
unpaired Student’s t-test assuming equal variance was performed to compare averages. For
each experiment, at least three biological replicates were analyzed. In vitro analyses were
repeated by at least two independent experiments. Where indicated, standard error of the mean
(SEM) measuring how far the sample mean of data is likely to be from true population mean, is




4.1 HIF-1α IS ACCOUNTABLE FOR LOW TUMORIGENIC
POTENTIAL OF CI DEFICIENT CANCER CELLS
Our group has already reported that in the presence of homoplasmic disruptive mtDNA muta-
tions, as seen in oncocytic tumors, cancer cells present with a severe mitochondrial CI damage
and lower tumorigenic potential than CI competent tumors (Kurelac et al., 2013). To mimic
the effects of disruptive mtDNA mutations in order to better understand their anti-tumorgenic
effects, 143B osteosarcoma, HCT116 colorectal human cancer cell lines and B16F10 murine
melanoma cell lines were genetically targeted for CI by knocking out its NDUFS3 subunit. We
hypothesized that these CI deficient tumors were associated with HIF-1α destabilization even
in hypoxia. The HIF-1α destabilization, as observed in CI deficient 143B and HCT tumors by
our group (Kurelac et al., 2019), could be attributed to high intracellular oxygen concentrations
and/or NADH accumulation which then consequently leads to an increased αKG/succinate
ratio in them (Calabrese et al., 2013). This data was also consistent with wide range of studies
that target OXPHOS pharmacologically in cancers resulting in decreased HIF-1α stability
(Selak et al., 2005; Bastein et al., 2017; Wang et al., 2015).
4.1.1 INTRODUCING THE HIF-TM IN CI DEFICIENT CELLS RES-
CUES THEIR TUMORGENIC POTENTIAL AND VESSEL MAT-
URATION
With the aim to prove that CI deficiency reduces tumor progression due to lack of HIF-1α
stabilization and subsequent inability to adapt to hypoxic environment, a constitutively and
non-degradable human form of HIF-1α , named HIF-TM was introduced into both 143B CI
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deficient (143B-/-) and HCT CI deficient (HCT-/-) human models. In parallel, a mock with
empty vector was introduced as a control. In order to evaluate the presence of a stable and
constitutively expressed HIF-1α in the HIF-TM cells, immunofluorescent staining was carried
out, which confirmed the translocation of HIF-TM into the nucleus in normoxia (Fig. 4.1A).
Western blot analysis further confirmed a higher expression of HIF-1α in the HIF-TM cells
compared to the mock, irrespective of oxygen concentration (Fig. 4.1B).

















Fig. 4.1 HIF-TM introduction ensures a stable, non-degradable HIF-1α protein and its translo-
cation to the nucleus (A)- Immunofluorescence of 143B-/- cells cultured in vitro and carrying
empty vector (Mock) or HIF-TM. Magnification 200x. (B) HIF-1α protein SDS-PAGE and
Western Blot analysis of 143B-/- cells carrying empty vector (mock) and HIF-TM, cultured in
1% O2 and 21% O2. Gamma tubulin was used as loading control.
Although in vitro models have been utilized as an important tool in cancer research, they
do not reflect the essential features of in vivo tumor-microenvironment, particularly important
when studying phenomena like hypoxia. Thus, to fully comprehend the inherent intricacy
of tumors, it is a pre-requisite to replicate them in vivo. Taking this into account, 143B-/-
and HCT-/- HIF-TM and Mock tumors were injected into nude mice to assess the effects of
introduction of the HIF-1α in the CI deficient cells on their tumorigenic potential.
In both osteosarcoma and colorectal cancer models of CI deficiency, the presence of HIF-
TM, which was confirmed by the western blot analysis (Fig. 4.2B), the xenografts grew
significantly larger than their controls (Fig. 4.2A), suggesting that inserting HIF-1α in CI
deficient cells was partially responsible for the rescue of their tumor growth. HIF-1 transacti-
vates a wide array of genes including those promoting angiogenesis and anaerobic metabolism.
Accordingly, RT-PCR analysis confirmed a higher expression of HIF-1 target genes SLC2A1,
LDHA and VEGF in the HIF-TM than in the Mock xenografts (Fig. 4.2C), corroborating that
xenografts expressing HIF-TM activated the HIF-1 regulated hypoxic signalling pathways.
Moreover, to exclude possibilities of an epistatic effect of the transcription factor in vivo,
HIF-TM was also introduced into 143B+/+ cells, which were then inoculated into the nude
mice. However, no significant effect on tumorigenic potential was observed upon HIF-TM
induction in CI competent model (Fig. 4.3), providing additional proof that lack of HIF-1α
transcription factor impaired tumorigenic potential of CI deficient cells.
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Fig. 4.2 Introducing HIF-TM in CI deficient cells rescues their tumorigenic potential (A) Tumor
growth curves of 143B-/- and HCT116-/- after injection into nude mice (for each cell line:
N=8, EXP=2). Data represent average tumor mass + SEM (*p<0.05,**p<0.01). Representative
images of tumor masses are shown. Bars=2cm. (B) SDS-PAGE and western blot analysis
of HIF-1α protein levels. Vinculin was used as a loading control. (C) qRT-PCR analyses of
xenografts for HIF-1 responsive genes SLC2A1, LDHA and VEGF. Data display mean+SEM;
N=3 (*p<0.05,**p<0.01, ***p<0.001).
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Fig. 4.3 HIF-TM does not induce increase in the tumorigenic potential of 143B+/+ tumors -
Tumor growth curve of the 143B+/+ Mock and 143B+/+ HIF-TM xenografts after subcutaneous
injection into nude mice. Data display mean+SEM. N=6, EXP=1.
Owing to their high metabolic demand, tumors rapidly exhaust the oxygen supply and
nutrients from the normal vasculature, and become hypoxic, which in turn drives the production
of angiogenic factors from the hypoxic tumor sites, triggering the vascularization of the tumor
mass. From this perspective, angiogenesis was investigated in the CI competent and CI deficient
models. The latter revealed several small, smooth muscle actin (SMA) negative and poorly
developed vessels, while CI competent tumors displayed SMA positive vessels, indicative of
mature vasculature (Kurelac et al., 2019). To understand whether HIF-1 activity is sufficient to
mediate tumor angiogenesis, vasculature was investigated also in CI deficient tumors harbouring
HIF-TM (Fig. 4.4). Immunohistochemical analysis of the CI deficient 143B and HCT HIF-TM
xenografts displayed a fully developed mature vasculature positive for the pericyte marker
SMA, while the Mock controls showed SMA negative, lumen free immature vessels (Fig. 4.4).
The fact that re-expression of constitutively active HIF-1α rescues the mature phenotype of the
vessels in CI deficient models, suggests that HIF-1α inactivation impairs tumor vasculature in
CI-deficient tumors.
Altogether, these data suggest that the antitumorigenic effect of CI deficiency tumors, at
least to a certain extent, is attributed to their inability to promote appropriate angiogenesis on
account of HIF-1α destabilization.
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Fig. 4.4 HIF-TM xenografts present with mature vessels positive for pericytes. Immunofluores-
cent staining analyzing vessel morphology of 143B-/- Mock and 143B-/- HIF-TM xenografts.
SMA (green) is fibroblasts marker, Endomucin (Endo-red) is vessels marker and DAPI (blue)
is nuclei marker.
4.1.2 INDUCING NDUFS3 KO IN B16F10 MURINE MELANOMA MODEL
LEADS TO CI INACTIVATION, INABILITY TO PERFORM OX-
IDATIVE PHOSPHORYLATION AND PREVENTS HIF-1α STA-
BILIZATION IN HYPOXIA
To investigate whether the lack of HIF-1α in CI deficient cells is generalized to other mam-
malian species and to eventually comprehend the effects of CI deficiency on its TME in an im-
munocompetent model, by taking into consideration the adaptive immune system, Crispr/Cas9
technology was used to obtain the knock-out (KO) of NDUFS3 gene in B16F10 murine
melanoma tumors. From the 451 cells seeded for clonal selection, 117 clones grew and were
expanded, and their NDUFS3 sequence was genotyped using Sanger sequencing (Fig. 4.5).
Out of 117 clones, 51 presented with a frameshift insertion or deletion, 11 of which were
homozygous mutants and 40 were heterozygous mutants. The following genotypes were found
among the homozygous mutants: c.289291insA, c.3234insA, c.30C > A, 16 base deletion
at c.325, c.329332delTC and c.330331insC. The latter clone harbored also a homozygous
c.328A > G mutation (Fig. 4.5). To take into consideration potential Crispr/Cas9 off-target
effects, 51 wildtype (WT) clones (NDUFS3 +/+) following the same selection procedure were
analyzed to identify appropriate controls. The western blot identified 10 clones in which
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Fig. 4.5 Sanger sequence identifying the NDUFS3 KO clones. Electropherograms compare the
wild type sequence D3-4 clone B16+/+ to one of the G4-2 B16-/- clone carrying homozygous
c.330331insC frameshift mutation. Moreover, the same clone also harbors a c.328A > G point
mutation. The mutated nucleotides are underlined and indicated in bold black.
NDUFS3+/+ clones (B16+/+) were checked for NDUFS3 and showed to express it and could,
thus, be used as controls.
The complete disruption of the CI in 143B and HCT NDUFS3 -/- cells was shown to
impair the cell capacity to use OXPHOS and grow in galactose only media (which forces
cells to rely on OXPHOS for energy requirements), as well as compromise their growth in
low glucose conditions (Kurelac et al, 2019). Thus, with the aim to identify B16 clones in
which the NDUFS3 knock-out is associated with OXPHOS defects indicating CI-deficiency,
cell proliferation in conditions of low glucose (5mM) and galactose were evaluated in 10
B16-/- clones and compared with the growth of eight control B16+/+ clones. Five B16-/-
clones presented with growth decrease when incubated in galactose only condition, four of
which presented also with growth decrease in low glucose media (Fig. 4.6B). In general, when
compared to B16+/+ controls, the B16-/- clones had lower net proliferation in stress conditions,
suggesting a reduced OXPHOS efficiency. The five clones positive for OXPHOS defect were
selected for further experiments.
To verify whether the lack of NDUFS3 had an impact on CI assembly and function, In-gel
NADH dehydrogenase CI activity was measured on two B16+/+ and five B16-/- clones to
examine the activity of CI. Out of the five B16-/- clones analyzed, two clones E6-1 and G4-2
displayed a significant decline of CI activity in comparison to the B16+/+ clones G4-5 and
D3-4 (Fig. 4.7A). Furthermore, western blot analysis on the isolated crude mitochondria from
the five B16-/- clones confirmed the absence of NDUFS3 protein expression in only two B16-/-
clones E6-1 and G4-2 (Fig. 4.7B).
Finally, to check our hypothesis that CI deficit is associated with lack of HIF-1 impairment,
HIF-1α protein levels were evaluated in the two B16-/- clones that lacked CI activity and
two B16+/+ clones after incubation in normoxia (21% O2) and hypoxia (1% O2). We found
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Fig. 4.6 The identified B16-/- cells from the NDUFS3 western blot cannot sustain proliferation
when cultivated in low glucose or compelled to depend on OXPHOS for energy production
in galactose media. (A) SDS-PAGE analysis followed by western blot identifies clones with
absence of NDUFS3 protein in this representative image. Actin is used as a loading control.
(B) B16-/- cells cannot sustain proliferation when cultivated in low glucose or compelled to
depend on OXPHOS for energy production in galactose media. Sulforhodamine B (SRB) assay
was performed in vitro on B16F10 clones incubated for 48 hours in low glucose (5mM) or
galactose (5mM). Data represent the percentage of cell proliferation (y axis) of each clone (x
axis) in the stress condition normalized to time zero. The dashed red line separates the B16+/+
and B16-/- clones. N=3, Exp=1.
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Fig. 4.7 The effect of NDUFS3 knock-out on CI assembly and function in selected B16-/-
clones. (A) CI-in gel NADH dehydrogenase activity following clear native page in the B16+/+
and B16-/- clones. Bovine heart mitochondria (BHM) were used as a positive control and 143B-
/- clone 1G5 was used as a negative control (B) Representative SDS-PAGE and Western Blot of
the mitochondrial lysates isolated from the clones analyzed in (B). Succinate dehydrogenase
subunit A (SDHA) was used as loading control.
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Fig. 4.8 B16-/- clones cannot stabilize HIF-1α expression. SDS-PAGE and Western Blot
analysis of HIF-1α expression in B16-/- E6-1 and G4-2 clones and B16+/+ G4-5 and D3-4
clones in normoxia (N) and 1 hour and 5 hours of hypoxic conditions (h). Actin is used as a
loading control.
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that both E6-1 and G4-2 B16-/- clones failed to show a stable HIF-1α expression even when
exposed to hypoxia (Fig. 4.8). Taken together, these data suggest that HIF-1α destabilization
is a general mechanism adopted by tumor cells with CI deficiency.
4.2 MACROPHAGE ABUNDANCE IN CI DEFICIENT OS-
TEOSARCOMAS IS ASSOCIATED WITH DOWNREG-
ULATION OF HIF-1-MIF AXIS
Although the CI deficient models display anti-tumorigenic potential, if allowed to grow they
progress to malignancy similar to their CI competent counterparts (Kurelac et al., 2019). It
is important to note that a severe respiration impairment, which is a characteristic feature
of CI deficient tumors, promotes metabolic reprogramming by switching from OXPHOS to
glycloysis that alters not only the cancer cells but also their TME. The interactions between the
cancer cells and the populations of their microenvironment immensely influence the fate of
the tumor. In particular, there is accumulating evidence supporting the involvement of TME to
sustain tumor progression and survival (Sousa et al., 2016; Quian et al, 2011; Orimo et al 2016).
In this context, with the aim of understanding the alternative mechanisms that the CI-deficient
tumors activate to progress despite the lack of a proper hypoxic response, their innate immune
cells and CAFs were analyzed.
4.2.1 MACROPHAGE ABUNDANCE IS ASSOCIATED WITH CI DE-
FICIENCY IN 143B XENOGRAFTS
Flow cytometry analysis of innate immune system namely, macrophages, neutrophils, dendritic
cells and natural killer cells were analyzed in 143B-/- and 143B+/+ xenografts at day 30
post injection (Fig. 4.9). The significant upregulation of neutrophil could be attributed to lot
of necrosis observed in 143B+/+ tumors as demonstrated by the histological staining (Fig.
4.10). There were no significant differences in the dendritic and natural killer cell contribution.
However, a significant and consistent increase in tumor associated macrophages (TAM) was
observed in 143B-/- tumors (Fig. 4.9). This finding was further corroborated by significant
increase in F4/80 (M2 macrophage marker) TAM infiltrations observed by immunofluorescence
on sections from the 143B-/- cancer masses (Fig. 4.11).
Overall, these data suggest that the macrophage abundance is a hallmark of CI deficient
tumors and is a possible effect of the HIF-1α inactivation in the 143B-/- tumors. In addition, our
data are also in agreement with previous reports that frequently associate high M2 macrophage
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Fig. 4.9 Macrophage infiltration is a phenotype of 143B-/- tumors. Flow cytometry analysis
of innate immune system populations in 143B. The contribution of macrophages (F4/80+),
neutrophils (Lys6G+), dendritic cells (CD11c+F4/80-) and natural killer cells (CD49b+) is
shown at day 30 post injection in ICRF nude mice. Data are mean+SEM. N= 4; (* P<0.05).
(Kurelac et al., 2019)
Fig. 4.10 143B+/+ tumors present with necrosis. Immunohistochemistry in 143B+/+ xenograft



































Fig. 4.11 143B-/- xenografts present with higher macrophage abundance. (A) Immunofluores-
cence staining of 143B xenografts for macrophage marker F4/80. (B) Representative graph
of the macrophage count of the 143B xenografts per field of view (FOV). Data displayed are
mean ± SEM N= 4; (* P<0.05).
numbers with increased vascular density and anomalies as seen in the CI deficient tumors
(Clear et al., 2010).
4.2.2 HIF-1-MIF AXIS CONTRIBUTES TO MACROPHAGE ABUN-
DANCE IN 143B CI DEFICIENT TUMORS
After establishing that macrophage infiltration is one of the adaptive mechanisms triggered
by the CI deficient tumors to maintain their growth, we aimed to investigate the various
mechanisms and factors responsible for its abundance. The activation of the TAMs towards
a pro-angiogenic phenotype is modulated by the stimuli in their surrounding TME and also
by the cytokine milieu to which they are exposed (Arango and Descoteaux, 2014). The local
cytokine microenvironment plays a significant role in tumorigenesis, tumor progression and
resistance to oncotherapy. The development of cytokines in tumor disease is studied for three
key purposes: first to understand and disclose tumorigenesis and immune escape mechanisms,
second, to classify biomarkers for cancer detection, prognosis and clinical follow-up, and finally
to assess them as potential cancer treatment immunotherapy targets (Kelso, 1998). Therefore,
human cytokine array was used to detect the relative expression levels of 36 human cytokines
in our 143B-/- and 143B+/+ xenograft derived supernatants (Fig. 4.12B). The array showed
a significant upregulation in the expression levels of IL-8 (CXCL8) and CXCL1, while MIF,
CXCL12, SERPIN-E1 and G-CSF levels were downregulated in the 143B-/- xenograft derived
supernatant (Fig. 4.12A).
Among the above cytokines, macrophage migration inhibitory factor (MIF), which although
exhibits pleiotropic functions, was of interest to us since hypoxia-induced HIF-1α activation is
implicated to stimulate its expression and it is also responsible for the inhibition of macrophage
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Fig. 4.12 MIF is one of the downregulated cytokine in HCT-/- tumors. (A) Blotting of super-
natants from 143B and HCT xenograft-derived cancer cells against the human cytokine array
(B) Table representing the coordinates of the cytokine in the kit and the representative graph of
the cytokine array analysis.
migration. Its expression level is directly associated with degrees of disease pathogenesis. In
addition, MIF is also associated in the regulation of hypoxia-induced angiogenesis. (Castro et
al., 2017; Abdul et al., 2018; Fu et al., 2010). Since MIF is also known for its endocrine and
enzymatic functions, the correlation between its intracellular protein levels and mRNA was
investigated next. To check for the difference in MIF gene expression and intracellular protein
levels, qRT-PCR and western blot analyses were carried out respectively.
MIF expression was also checked in the in vitro cultures grown in hypoxia since it is one of
a HIF-1 α target gene. Expression of the MIF was down regulated in the 143B-/- with respect
to the 143B+/+ tumors in xenografts after 30 days post inoculation (Fig. 4.13A) and even in
hypoxia in vitro (Fig. 4.13B) indicating that the MIF downregulation could be a consequence
of impaired response to hypoxia in 143B-/- tumors. This was further corroborated by WB
analysis where 143B-/- showed MIF down regulation as presented by the lower band intensity
(Fig. 4.13C).
Furthermore, 143B-/- complemented with HIF-TM were analysed to confirm if HIF-1 is
responsible for MIF regulation in these models. Indeed, in 143B-/- HIF-TM xenografts, there
was an up regulation of MIF expression in comparison to the Mocks and was evidenced by
both qRT-PCR in xenografts (Fig. 4.14A) and in vitro (Fig. 4.14B) and also with WB analysis,
providing further evidence that MIF followed HIF-1 regulation in these cells (Fig. 4.14C).
Among other, TAMs are known to guide angiogenesis in tumors (Zhu et al., 2017), which
generated hypothesis that increased TAM infiltration could be a compensatory mechanism
to survive the inactivation of HIF-1α mediated angiogenesis in 143B-/- tumors. Thus, the
























Fig. 4.13 143B-/- tumors demonstrate a higher MIF expression compared to 143B+/+. (A)
qRT-PCR analysis of MIF expression in xenografts and (B) in vitro after 24H incubation in
hypoxia (C) SDS-PAGE and Western Blot analysis of MIF expression in xenografts. Actin
was used as a loading control. Data display mean ± SEM. N = 3; (* P<0.05; ** P<0.01;
***P<0.001).
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Fig. 4.14 143B-/- HIF-TM tumors exhibits a higher MIF expression compared to 143B-/- Mocks
due to presence of stable HIF-1α . (A) qRT-PCR analysis of MIF expression in xenografts
and (B) in vitro (C) SDS-PAGE and Western Blot analysis of MIF expression in xenografts.
Vinculin was used as a loading control. Data display mean ± SEM. N = 3; (* P<0.05; **
P<0.01; ***P<0.001).
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Indeed, the 143B-/- HIF-TM masses showed a reduced F4/80 macrophage numbers compared
to their 143B-/- Mock controls (Fig. 4.15A and Fig. 4.15B), suggesting that HIF-1α inactivity
is partly responsible for TAM recruitment in 143B-/- tumors.







































Fig. 4.15 143B-/- HIF-TM xenografts arrest macrophage infiltration. (A) Immunofluorescence
staining of 143B-/- Mock and 143B-/- HIF-TM xenografts for macrophage marker F480
represented in red and DAPI nuclei marker represented in blue. Magnification 40X. (B)
Quantification of the macrophage count of 143B-/- Mock and 143B-/- HIF-TM xenografts per
field of view (FOV) are represented by the graphs. Data displayed are mean ± SEM N= 8;
(***P<0.001).
In conclusion MIF-HIF-1 axis disruption is one of the factors accountable for macrophage
abundance in 143B-/- tumors.
4.2.3 MACROPHAGE ABUNDANCE IS ASSOCIATED WITH CI DE-
FICIENCY AND HIF-1-MIF DOWNREGULATION IN THE OR-
THOTOPIC OSTEOSARCOMA MODEL
The translatability of animal models is one of the biggest difficulties researchers face in
preclinical oncology studies. It is a daunting challenge to accurately replicate human diseases
to study the effects of novel therapeutics. Models are required in which the cancer cells
interact with the complex microenvironment to recapitulate each form of cancer more faithfully.
Only in the organ where the tumor has first developed can this relevant microenvironment be
established. Due to the establishment of an organ-specific tumor microenvironment, which may
vary in each type of cancer, orthotopic tumor models are clinically more important than their
subcutaneous equivalents. Thus, a humanized bone-forming ectopic xenotransplantation model,
recapitulating the bone like microenvironment was applied as a pseudo-orthotopic approach
to grow osteosarcoma cells. In particular, already established 143+/+ and 143B-/- models
were used to corroborate the findings obtained in subcutaneous xenografts. The histology of
these mesenchymal cell populations in the humanized bone xenografts was analyzed to study
4.2 MACROPHAGE ABUNDANCE IN CI DEFICIENT OSTEOSARCOMAS IS
ASSOCIATED WITH DOWNREGULATION OF HIF-1-MIF AXIS 55
the TME specific to osteosarcoma progression, which identified 143B-/- to have more TAM
contribution (Fig. 4.16), which was consistent with our previous findings that presented the
same phenomenon in the 143B-/- and HCT-/- nude mice xenografts (Kurelac et al., 2019).
Fig. 4.16 143B-/- tumors had higher macrophage infiltration. Representative images of im-
munohistochemistry analysis for macrophage marker F4/80 in 143B xenografts at day 30 in
trabecular bone (upper images) and infiltrating the tissue (lower images). Scale bars: 50 µm.
Data displayed are mean ± SEM; (* P<0.05; ** P<0.01).
Moreover, to check if these orthotopic 143B-/- tumors were also characterized by lack of
HIF-1α stabilization like our 143B-/- and HCT-/- tumors, the expression of HIF-1α and also
their vasculature were checked at day 30 and day 60 post inoculation. Indeed orthotopic 143B-/-
displayed no HIF-1α stabilization and small, lumen-free and SMA-negative vessels, while
their 143B+/+ controls showed a HIF-1α mediated mature, SMA positive vascularization as
evidenced by the IHC analysis. Although, CI-deficient tumors associated with a higher number
of vessels due to lack of HIF-1α , they were relatively smaller in size compared to the control.
Moreover they also lacked pericyte marker SMA (Fig. 4.17A and Fig. 4.17B).
Additionally, to identify the factors responsible for TAM recruitment in the 143B-/-
xenografts ,its supernatants were blotted on a human cytokine array and indeed MIF was
found to be downregulated in the 143B-/- tumors with respect to 143B+/+ tumors (Fig. 4.18).
In addition, it is interesting to note that morphological analysis revealed that 143B+/+
controls were characterized by loss of osteocytes with empty osteocytic lacunae in the min-
eralized bone matrix and by intensive necrosis, while the 143B-/- tumors presented with no
necrosis and higher osteocytes and osteoblasts in the trabecular bone confirming that the 143B-/-
pseudo-orthotopic xenografts preserved osteocytes and osteoblasts. This provided evidence of




















































































Fig. 4.17 143B-/- xenografts are associated with HIF-1α destabilization and demonstrate higher
immature vessels count, negative for pericytes. (A) Immunohistochemistry analysis of the
HIF-1α in 143B+/+ and 143B-/- osteosarcomas xenografts. Scale bars: 50 µm. (B) Immunoflu-
orescent staining analyzing vessel morphology in CI-deficient and competent osteosarcoma
xenografts. SMA (green) is fibroblasts marker, Endomucin (red) is vessels marker and DAPI
(blue) is nuclei marker. Quantification of the total number of vessels per field of view (FOV),
percentage of pericyte negative vessels (%Endo+SMA-) and the average vessel size in 143B+/+
and 143B-/- tumors are represented by the graphs. Data displayed are mean ± SEM. N=4; (*
P<0.05; ** P<0.01; ***P<0.001; NS= Not significant). N=4.
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Fig. 4.18 143B-/- xenograft derived supernatant is associated with MIF downregulation. In
xenograft-derived cell culture supernatants, the results of cytokine screening. The arrows show
the dot blots of the cytokine array for MIF.
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Fig. 4.19 143B-/- pseudo-orthotopic xenografts preserved bone microenvironment. Hema-
toxylin and eosin staining of the trabecular bone in the 143B xenografts at day 30 and day
60 post implantation.; osteoblasts are indicated by the asterisks, osteocytes by arrows and the
neoplastic cells are circled. Scale bars: 100µm. Quantification of osteocytes and osteoblasts in
the osteosarcoma xenografts are represented by the graphs. Data displayed are mean ± SEM; (*
p < 0.05, ** p < 0.01).
Orthotopic tumor models are more clinically suited than subcutaneous models, on account
of the formation of an organ-explicit TME, which can vary in each malignant growth type. The
penetrating immune cells from subcutaneous mouse tumors can vary from those in orthotopic
tumors from a similar model. Altogether, these data provide us with additional evidence that
macrophages recruitment is one of the prominent phenotype associated with 143B-/- tumors
and is most likely a consequence of HIF-1-MIF axis disruption.
4.3 MACROPHAGE ABUNDANCE IN COLORECTAL CI
DEFICIENT TUMORS IS NOT ASSOCIATED WITH
DEREGULATION OF HIF-1-MIF AXIS, REGARDLESS
OF P53 STATUS
To understand if macrophage abundance is a generalizable phenomenon in CI deficient tumors,
the TME of HCT tumors were investigated. Flow cytometry analysis of innate immune system
namely macrophages, dendritic cells, neutrophils and natural killer cells were analyzed also in
HCT-/- and HCT+/+ xenografts at day 30 post injection. There were no significant differences
in the neutrophils, dendritic and natural killer cells contribution. However, a significant increase
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in TAM was observed in HCT-/- tumors as well (Fig. 4.20). Thus, it may be concluded that
macropahge infiltration was a common adaptive mechansim activated by CI deficient tumors.
Fig. 4.20 Macrophage infiltration is a phenotype of HCT-/- tumors. Flow cytometry analysis of
innate immune system populations in HCT tumors. The contribution of macrophages (F4/80
+), neutrophils (Lys6G +), dendritic cells (CD11c + F4/80-) and natural killer cells (CD49b +)
is shown at day 30 post injection in ICRF nude mice. Data are mean + SEM. (* P<0.05).
4.3.1 MIF IS NOT DOWNREGULATED IN HCT CI DEFICIENT TU-
MORS, DESPITE LACKING HIF-1 ACTIVITY
Since we found that the downregulation of MIF cytokine was involved in 143B masses, we
wanted to understand whether the same mechanism could be associated with macrophage
abundance in HCT models as well. qRT-PCR was done to analyze the MIF mRNA levels
in HCT xenografts. Although there was a significant downregulation of MIF after 10 days
in the HCT-/-, there was no difference in MIF expression after 30 days in vivo (Fig. 4.21A).
MIF expression was also checked in controlled conditions in vitro in hypoxia to understand
better the differences we see in vivo. There was no difference in MIF expression in vitro (Fig.
4.21B) suggesting that after initial decrease, MIF levels are recovered in the HCT-/- tumors
eventually. The incongruous expression between mRNAs and intracellular proteins highlights
the significance of posttranscriptional regulatory mechanisms that can be revealed only by
integrated studies of both intracellular proteins and mRNAs in cell growth or disruption. Thus,
the MIF intracellular protein expression was checked in HCT tumors. However, there were no
changes in the MIF intracellular protein expression of the HCT-/- and HCT+/+ masses analyzed
by WB at 30 days post injection, which showed similar band intensities (Fig. 4.21C). This















































Fig. 4.21 HCT+/+ tumors demonstrate no significant changes in MIF expression compared to
HCT-/- counterpart. (A) qRT-PCR analysis of MIF expression in xenografts and (B) in vitro
after 24H incubation in hypoxia (C) SDS-PAGE and Western Blot analysis of MIF expression
in xenografts. Actin was used as a loading control. Data display mean ± SEM. N = 3; (NS= not
significant).
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4.3.2 HIF-1 IS NOT ACCOUNTABLE FOR MACROPHAGE ABUN-
DANCE IN HCT CI DEFICIENT TUMORS
As mentioned previously, MIF is a HIF-1 target and since we did not see any difference in MIF
status in HCT model we hypothesized that mechanism other than HIF-1 could be involved in
macrophage abundance in colorectal cancer setting. To corroborate this, we next tested whether
the macrophage abundance depends on HIF-1 activity in HCT-/- tumors. The macophage count
was analyzed in the HCT-/- HIF-TM and HCT-/- Mock xenografts. There were no differences in
the macrophage count between the HCT-/- HIF-TM and Mock samples, demonstrating that the
mechanisms involved in the macrophage abundance in the HCT-/- tumors is infact independent





































Fig. 4.22 HCT-/- HIF-TM xenografts has no significant changes in macrophage count compared
to HCT-/- mocks. (A) Immunofluorescence staining of HCT xenografts for macrophage marker
F480 represented in red and DAPI nuclei marker represented in blue. Magnification 40X. (B)
Quantification of the macrophage count of the HCT-/- Mock and HCT-/- HIF-TM xenografts
per field of view (FOV) are represented by the graphs. Data displayed are mean ± SEM. N = 4;
(NS= Not significant).
Moreover, the incorporation of HIF-TM did not result in any significant changes in MIF
expression in the HCT-/- HIF-TM and Mock as evaluated by both transcriptional in vivo
(Fig. 4.23A), in vitro (Fig. 4.23B) and translational regulation (Fig. 4.23C), indicating that
mechanisms other than downregulation of HIF-1-MIF axis are involved in TAM abundance in
HCT tumors.
Collectively, the data indicate that the difference in MIF expression is tissue specific and
that the macrophage abundance may be a consequence of HIF-1α/MIF axis disruption in







































































Fig. 4.23 HCT-/- HIF-TM tumors show similar MIF expression compared to HCT-/- Mock
irrespective of presence of HIF-1α . (A) qRT-PCR analysis of MIF expression in xenografts
and (B) in vitro (C) SDS-PAGE and Western Blot analysis of MIF expression in xenografts.
Vinculin was used as a loading control. Data display mean ± SEM. N = 3; (NS= not significant).
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4.3.3 LACK OF MIF DOWNREGULATION IN CI DEFICIENT TU-
MORS DOES NOT DEPEND ON p53
We have demonstrated that MIF is not regulated by HIF-1 in the HCT models as compared to
143B models. It is important to note that our 143B models have TP53 with R156P mutation,
while our HCT models lack p53, disrupted through homologous recombination (Bunz et al.,
1999). p53 is a well-known ‘guardian of genome’ and tumor suppressor frequently mutated in
cancer. MIF was first reported as a negative regulator of p53 by Hudson et al., 1999. Since
then, several studies have validated MIF as a significant endogenous regulator of the expression
and function of p53 in a variety of biological processes (Kleemann et al., 2000; Mitchell et
al., 2002). There is compelling proof that overlapping pathways mediate the effects of MIF
on cell survival and tumorigenesis, in which MIF and p53 functionally antagonize each other
in the cell (Fingerle-Rowson, Petrenko, 2007). Therefore, we hypothesized that the lack of
MIF downregulation in HCT-/- model, as seen in 143B-/-, could be due to lack of p53 in the
HCTs. Thus, to eventually comprehend the mechanism behind the TAM infiltration in the
HCT CI deficient models, the relation between HIF-1α , MIF and P53 was investigated next.
HCT NDUFS3-/- p53-/- cell lines were transfected with wildtype p53, R156P mutated p53
or mock empty vector control (PMSCV) and were subjected to hypoxia or normoxia for 24
hours. To verify the transfection of p53 to make sure there were no technical issues, WB
analysis was carried out, which confirmed the expression of the WT and Mut p53 in HCT-/-
cell lines, both in normoxia and hypoxia (Fig. 4.24B). Moreover, the appropriate activation
of p53 was confirmed by qRT-PCR analysis of p53 responsive genes P21 whose expression
was upregulated in WT and Mut p53 transfected cells as compared to the PMSCV control(Fig.
4.24C). By comparing the MIF expression against HCT-/- PMSCV mock controls we observed
that HCT-/- showed no difference in MIF expression between hypoxia and normoxia when they
lacked p53, however they displayed a substantially higher MIF expression in hypoxia compared
to normoxia after the p53 transfection with WT or Mut as indicated by the qRT-PCR (Fig.
4.24A), which was antithesis of what we had predicted. In particular, an increased MIF levels
in hypoxia was detected in the presence of wild type p53 (Fig. 4.24A). However, intracellular
MIF showed no difference in its protein expression in HCT-/- cells, regardless of p53 status or
oxygen concentrations (Fig. 4.24B).
Based on our studies, we can conclude that the HCT-/- cells showed a p53 dependent
MIF upregulation. Unexpectedly, incubation in hypoxia significantly increased HCT-/- MIF
expression further despite their inability to activate HIF-1, indicating, p53 upregulated MIF
in hypoxia, independent of HIF-1α stability. Therefore, p53 does not downregulate the MIF
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Fig. 4.24 MIF upregulation is P53-dependent and is significant in hypoxia but not normoxia in
presence of a defective CI. (A) RT-PCR analysis of MIF expression in HCT-/- with PMSCV
mock or WT P53 or Mut P53 transfected cells after a total RNA extraction, incubated 24h in
normoxia or hypoxia. HCT-/- p53 PMSCV cell cultured in normoxia used as a control (B)
SDS-PAGE and Western Blot analysis for MIF and p53 expression of the same cultured in
normoxia or incubated in hypoxia for 24h. Actin was used as a loading control. (C) qRT-PCR
analysis of P21 in HCT-/- cells with either PMSCV control, WT or Mut P53 genotype incubated
in normoxia (21% O2) or hypoxia (1% O2) for 24 hours. Data are mean ± SEM. N = 3; (*
P<0.05; ** P<0.01; ***P<0.001).
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4.4 NINE METABOLITES IDENTIFIED AS POSSIBLE FAC-
TORS DRIVING MACROPHAGE ABUNDANCE IN CI
DEFICIENT TUMORS
Although we suggest disruption of HIF-1-MIF axis as a possible mechanism of macrophage
attraction in 143B-/- tumors, we were not able to identify any factors linking the CI deficiency
to macrophage abundance in HCT tumors. Moreover, pharmacological targeting of MIF
downregulation to prevent TAM abundance in CI deficient tumors is difficult to achieve.
Thus, we next searched for further factors involved in TAM abundance in CI deficient tumors.
Medical science has been revolutionized by high-throughput technologies, such as proteomics
and metabolomics, which are now integrated into biological researchers’ regular methodology
to identify essential networks and signalling pathways that can play an important role in cancer
metabolic control. In line with this, to identify the specific molecular/metabolic targets that
could contribute to the recruitment of the TAMs in the CI deficient tumors, to eventually target
them to improve the anti-cancer effects of CI inhibition, proteomics and metabolomics analyses
were carried out on the 143B and HCT secretome (post vivo conditioned media).
4.4.1 PROTEOMICS DOES NOT IDENTIFY COMMON SECRETED
PROTEINS BETWEEN CI-DEFICIENT 143B AND HCT CELLS
Small proteins such as cytokines help to regulate nearly all-immune processes and enables
immune cells to communicate; they are secreted through interaction with a pathogen- or
damage-related molecular pattern or an antigen from immune cells. To identify the potential
common factors involved in TAM recruitment by the CI-deficient cancer cells, proteomics
was performed on the conditioned media of osteosarcoma and colorectal cancer, to expand the
cytokine array analysis to the whole secreted proteome.
In both 143B and HCT model, the principal component analysis (PCA) analysis showed two
distinct clusters for the two different groups being compared (Fig. 4.25A), meaning that there
was no variation within each compared groups. The volcano plots with threshold -Logp=1 were
obtained to visualize significantly upregualted or downregulated proteins from the proteomics
data (Fig. 4.25B). Eight proteins and 32 proteins were identified as upregulated in the 143B
and HCT CI-deficient xenografts, respectively. On the other hand, eight proteins in 143B
and 53 proteins in HCT were downregulated in the CI-deficient xenografts. For example, the
upregulated secreted proteins in the 143B deficient included LOXL2, TIM and MSMP, whereas
HCT deficient cells secreted GPI, FABP5, NCL and FEN1. However, after analyzing data









Fig. 4.25 No common secreted proteins between 143B and HCT. (A) Principal component
analysis (PCA) of the proteomics data of 143B and HCT CI-deficient and CI-competent models
(B) Volcano plots presenting the proteomics summary of the post ex vivo conditioned media of
osteosarcomas 143B and colorectal HCT cancers (B) Venn diagrams using the VENNY 2.1
software showing overlap of the proteomics data of 143B and HCT secretome.
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cells (Fig. 4.25C), suggesting that there was no common secreted proteins upregulated or
downregulated between 143B and HCT.
4.4.2 METABOLOMICS ANALYSIS IDENTIFIES NINE METABOLITES
SPECIFICALLY SECRETED BY CI-DEFICIENT MODELS
There is a new emerging concept indicating that metabolites may regulate cytokine like effects,
by modulating the activity of specific enzymes, proteins or transcription factors as descried in
detail in the review by Zaslona and O’Neill (2020). Thus, metabolomics analysis was carried
out on the secretome of the CI deficient and CI competent ex vivo cultures, to identify the
small molecule types like fatty acids, carbohydrates, amino acids and other metabolites that
could be involved in modifying TME of CI deficient cancers. In both 143B and HCT, the
PCA analysis showed two distinct clusters for the two different groups being compared (Fig.
4.25A), confirming there was no variation within each compared groups. The homogeneous
distribution of metabolites within WT versus KO secretomes is furthermore evident from
hierarchical clustering (Fig. 4.25B). Eight upregulated metabolites that included ribose, ribulose,
proline, asparagine etc were found in 143B+/+ secretome, and 21 downregulated metabolites
including citrulline, serine, aspartate among others were identified in 143B-/- secretome . 15
upregulated metabolites that included cytidine, proline, taurine, glycine etc were recognized
in HCT+/+ secretome and 18 downregulated metabolites including aconitate, adenosine, beta
alanine among others were identified in HCT-/- secretome. Out of the total 21 downregulated
metabolites in 143B-/- and 18 downregulated metabolites in HCT-/- analyzed, the VENNY 2.1
software overlapping the metabolomics data revealed nine metabolites secreted by CI deficient
cells common to both the cancers (Fig. 4.25C). These include lactate, 2HG, Fumarate, Malate,
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Fig. 4.25 LC-MS analysis reveals nine common metabolites between 143B and HCT condi-
tioned media. (A) Principal component analysis (PCA) of the metabolomics data of 143B and
HCT CI-deficient and CI-competent models. The CI-deficient 143B and HCT is represented in
green and the CI-competent 143B and HCT tumors are represented in red (B) HeatMap analysis
of the metabolites after post ex vivo conditioned media based LC-MS analysis in 143B+/+ &
143B-/-osterosarcomas and HCT+/+ & HCT-/-colorectals. Data was mean normalized, log
transformed and paretoscaled. The color scale indicates the relative expression levels of the
metabolites across all samples(C) Venn diagrams using the VENNY 2.1 software showing
overlap of the metabolomics data of 143B and HCT revealed nine secreted metabolites common
to both.
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There are already indications in the literature that metabolites may exert immunomodulatory
effects. For example, KIC and KMC are the branched chain keto acids (BCKAs) that have been
reported to modulate the tumor-associated macrophages, contributing to their role in tumor im-
munosuppression in glioblastoma (Silva et al., 2017) In addition, high αKG/succinate ratio, as
seen in our CI deficient tumors, resulted in the alternative M2 activation of macrophages, includ-
ing engagement of fatty acid oxidation (FAO) and Jmjd3-dependent epigenetic reprogramming
of M2 genes (Liu et al., 2017).
Fig. 4.26 Metabolites significant in both osteosarcomas 143B and colorectal HCT cancer
Next, the obtained significantly upregulated or downregulated secreted metabolites were
subjected to pathway and enrichment analysis based on Metaboanalyst 4.0 to identify and
interpret patterns of metabolite changes in a biologically relevant way. The associated metabolic
pathways are shown in (Fig. 4.27). As a possible target pathway, the pathway impact value
determined from pathway topology analysis of > 0.1 was filtered out. Glutamine and glutamate,
pyruvate biosynthesis, alanine, aspartate and glutamate metabolism were the most important
metabolic pathways affected by 143B-/- and HCT-/- tumors compared to the 143B+/+ and
HCT+/+ tumors respectively (Fig. 4.27A). The three important metabolic pathways were
all related with amino acid metabolism, suggesting that the latter might play a major role in
assisting the adaptive mechanism of CI deficient cells to grow. In addition, the metabolite set
enrichment analysis indicated that glycolysis, selenocompound metabolism, glutamine and
glutamate metabolism, and pyruvate metabolism, valine, leucine, and isoleucine degradation,
and alanine metabolism are the top common metabolite concentrated sets being altered in CI
deficiency tumors compared to the CI competent tumors (Fig. 4.27B). All metabolite sets were
directly associated with amino acid metabolism. Furthermore, there were pathways known
to relate to the suppression of cancer, one of the significant pathways being selenocompound
metabolism. The potential for the anticancer effects of the micronutrient element selenium was
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demonstrated previously (Bartolini et al., 2017). All together, the metabolite set enrichment
analysis provides further evidence that amino acid metabolism, glycolysis, glutaminolysis
could be a key common mechanisms differentially regulated in the CI deficient cells for the
maintenance of their growth.
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Fig. 4.27 Summary of pathway analysis of the 143B and HCT xenograft derived supernatants
showing glycolysis and selenocompound metabolism that was the most disrupted pathways.
(A) The matched paths are all seen as circles. The color of each circle is dependent on p-values
(in the subsequent pathway, darker colors reflect more important changes in metabolites), while
the size of the circle corresponds to the impact score of the pathway. The most influenced
pathways with high scores of statistical importance are annotated. The x-axis represents the
pathway impact value computed from pathway topological analysis and -log of the P-value
obtained from pathway enrichment analysis is represented as the y-axis. (B) Overview of the
metabolite set enrichment analysis in 143B and HCT post ex vivo conditioned media. The
intensity of the color is correlated with the degree of statistical importance of each pathway
(highly significant - red, not significant - white), while the length of each bar reflects the fold




In the last decade, 70 years after Warburg identified aerobic glycolysis as a characteristic of
cancer cells, cancer metabolism has undergone resurgence. The vast variations between tissues,
tumor types and intratumor heterogeneity have been elucidated by a wide variety of techniques.
Despite a broad knowledge of metabolic regulation based on nearly a century of biochemistry
studies, our knowledge of how pathways are regulated to promote cell proliferation remains
incomplete. Further knowledge of precisely how cells control nutrient flux into pathways
needed for biosynthesis in particular genetic contexts would result in success in targeting cancer
metabolism. Understanding the metabolism of tumor cells involves the use of techniques to
test metabolite flux and pathway modulation that are not often used in the development of
cancer drugs. However, provided that all cancer cells rely on metabolic changes to sustain
their growth, targeting the metabolism has the potential to impact cancers arising from many
different tissues.
Targeting mitochondrial CI is considered a promising anti-cancer therapeutic strategy in
recent years (Akatsuka et al., 2016; Bastein et al., 2017). Particularly, CI inhibitor metformin
has given encouraging results in experimental and clinical settings for the treatment of solid
cancers (Wheaton et al., 2014; Gong et al., 2016; Higurashi et al., 2016). Severe CI deficiency
has been shown in low-proliferative, indolent oncocytic tumors where HIF-1α stabilization
is prevented by metabolic rearrangements following CI disassembly (Porcelli et al., 2010)
leading to the inability of cancer cells to respond to hypoxia. The reduction of stabilized
HIF-1α is accounted by the accumulation of α-KG and O2 (Tennant et al., 2009; Hagen
et al., 2003; Kurelac et al., 2019). This results in pseudonormoxic feature preventing the
tumor from developing a warburg phenotype and progressing to malignancy. In addition,
genetically targeting CI in various cancer types to prompt their conversion to oncocytomas,
lead to a lack of HIF-1α while accumulating defective mitochondria and showed impaired
metabolic flexibility in hypoxia (Calabrese et al., 2013; Gasparre et al., 2011). Extending this
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idea, using Crispr/Cas9 technology, Ndufs3 was targeted to abolish CI activity in B16F10
murine melanoma cells to check if HIF-1α destabilization was a generalized phenomenon in
mammalian species other than humans. Indeed, two clones, which represented the phenotype
of our already established CI deficient 143B and HCT cells (Kurelac et al., 2019) that lacked
CI activity demonstrated that they could not stabilize HIF-1α expression even in hypoxia in
vitro. Of note, the absence of an adaptive immune system in immuodeficient mice such as the
nude mice used in the previous studies prevents the investigation of anti-tumor metabolic or
immune response treatments. Therefore the B16-/- clones will be eventually used to understand
the complete effects of CI deficiency on its TME and to corroborate our findings in this study
in an immunocompetent model by taking into consideration the adaptive immune system.
There has been conflicting evidence on the effects of CI targeting on its TME. Recently it was
observed that tumor associated macrophages might be involved in compensatory mechanisms
triggered by targeting CI in several solid cancers (Kurelac et al., 2019). On a similar note,
it has recently been suggested that mitochondrial function needs to be maintained in order
to respond to immunotherapy (Harel et al., 2019). In addition, by knocking out CI using
experimental small interfering RNA, reduced 1L-2 and 1L-4 secretion were demonstrated
by the activated T cells. By blocking 1L-4, known to be associated with differentiation of
helper CD4+ T cells into Th2 cells through CI inhibition promoted the pro tumorigenic T
regs (Kaminski et al., 2010). Conversely, others have shown that inhibiting CI in cancer cells
reduces myeloid derived suppressor cell activity (Uehara et al 2019) and actually improves
T-cell cytotoxicity (Eikawa et al., 2015). Moreover, CI blockade, however, also has tumor-
promoting effects, leading to increased lactate content and expression of VEGF in cancer
cells, promoting tumor growth in mice (Chaube et al., 2015). These opposing observations
prompt for a more detailed investigation of the effects of CI inhibition on individual TME
cell populations. It is rational to suggest that the loss of HIF-1α threatens the progression of
CI-deficient masses due to the large number of pro-survival mechanisms triggered by HIF-
1α . In this present study, we have provided evidence for such hypothesis by complementing
CI-deficient cells with a non-degradable and stable HIF-TM. Introducing the HIF-TM into
the 143B-/-HIF-TM and HCT-/-HIF-TM cells rescued their tumorigenic potential in vivo in
addition to upregulation of HIF-1 target genes SLC2A1, LDHA and VEGF as compared to
the mock controls. But this is not surprising in itself; because it has been extensively shown
by other groups that knockdown of HIF slows down the tumor progression. Indeed loss of
HIF-1 reduced tumor progression in several cancer models (Schwab et al., 2012; Gillespie et al,
2007) and also by authoritative groups such as Semenza’s (Lee et al., 2009) and Simon’s group
(Shay et al., 2014). By decreasing oxygen intake and increasing its supply, HIF-1 controls the
expression of several genes that assist cells to respond to hypoxic conditions. This typically
77
entails transferring the energy metabolism to the less oxygen consuming glycolytic pathway
and activating the angiogenic genes to increase vascular supply to the hypoxic areas. Indeed
we see that degradation of HIF-1α impairs tumor vasculature in CI-deficient osteosarcoma
and colorectal tumors (Kurelac et al., 2019). Moreover, through suppression of the HIF-
1α/VEGF signalling pathway, aloe-emodin, an antiangiogenic agent, diminished hypoxia-
induced retinal angiogenesis (Wu et al., 2016). Similarly, inhibition of HIF-1α decreased
retinal neovascularization in hypoxic condition (Iwase et al., 2013). In line with this, both
143B-/-HIF-TM and HCT-/-HIF-TM tumors rescued the vessel maturation demonstrating that
stimulation of vasculogenesis by HIF-1 contributed to the rescue of their tumorigenic potential.
However, the CI deficient tumors still persist and present with vascularization, which raised the
question of what other mechanisms could be guiding their angiogenesis in the absence of HIF-1.
Signals produced within the TME not only mobilize myeloid cells from the bone marrow (or
their precursors), but also recruit them into tumors from the bloodstream and then activate
their pro-angiogenic functions (De Palma et al., 2017). In this respect, our observation of a
different histological architecture in CI-deficient masses compared to the CI competent masses
revealed that difference in their TME composition could be responsible for the alternative,
HIF-1 independent vascularization in CI deficient tumors. Indeed the 143B-/- and HCT-/-
xenografts presented with a higher infiltration of TAM with respect to their CI competent
masses.
Interestingly, 143B+/+ tumors additionally presented with an upregulated neutrophil expres-
sion, which is in line with the fact that CI competent masses are enriched with necrotic sites,
to which neutrophils are attracted. (Patricia et al., 2020). Furthermore, the accumulation of
neutrophils is a process that is tightly controlled by cytokines. The increased cytokine levels of
G-CFS and CXCL12 in 143B+/+ tumors, which are known regulators of neutrophil release and
modulates their retention at inflammatory sites respectively, provides additional explanation for
the elevated neutrophil levels (Semerad et al., 2002; Isles et al., 2019).
Multiple immature vessels like that found in our CI deficient tumors are associated with
TAMs proangiogenic activity, which may aggravate the tumor progression. It is worth noting
that myeloid cells, especially macrophages, play an important role in the abnormalization of
blood vessels and restrict the transmission of chemotherapeutic agents into tumors (Chen et
al., 2013). For example, studies by Rolny et al speculate that by expressing elevated levels or
various types of angiogenic stimuli, M2-polarized TAMs make vessels irregular and immature
as seen in our CI deficient models. Upregulation of angiogenic M2-cytokines (IL-10, CCL22,
IL-1β , TNFa) or downregulation of angiostatic M1-cytokines (IFN-β , CXCL10, IL-12) can
also lead to abnormalization of vessels (Rolny et al., 2011; Chen et al., 2013; Murdoch et al.,
2013). Because their vasculature has been correlated with the TME of CI-deficient tumors, we
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believe that TAMs could be involved in compensatory processes activated to bypass the inability
of CI-deficient tumors to enable angiogenesis induced by HIF-1α . This is further confirmed
by the fact that introducing HIF-TM decreased the macrophage count in the 143B-/-HIF-TM
tumors as compared to the 143B-/-Mock controls, meaning that HIF-1α destabilization was
one of the factors contributing to TAM recruitment.
In immune evasion, the hypoxic tumor microenvironment plays a fundamental function. In
fact, tumor hypoxia is thought to play a pivotal role in TAM phenotypic regulation, as hypoxic
TAMs release variables that assist in tumor development, immunosuppression of cancer, and
angiogenesis (Casazza et al ., 2013; Du et al., 2008). The accumulation of macrophages in
hypoxic / necrotic regions could account for two possible mechanisms as explained by Henze
and Mazzone in their review, the attraction of macrophages by a cytokine gradient and the
impaired mobility of macrophages within these areas (Henze and Mazzone, 2016). This is in
contradiction to the macrophage infiltrations we observe in our non-necrotic, hypoxia lacking
CI deficient models.
In addition, CI deficient osteosarcoma tumors presented with MIF downregulation, a mech-
anism recently associated with macrophage-mediated vascularization triggered as a compen-
satory reaction to anti-VEGF therapy (Castro et al., 2017) which is in line with the hypothesis
that lack of HIF-1-guided angiogenesis triggers TAM abundance. This is also further evidenced
by the decrease in MIF expression after introducing the HIF-TM into the 143B-/-HIF-TM
tumors. As mentioned before, MIF is a known HIF-1-responsive gene. It was also shown that
MIF promoted Warburg effect by upregulating HIF-1α and the promotional influence of MIF
on the Warburg effect was effectively eliminated by the knockdown of HIF-1α (Li et al., 2018).
MIF, among other functions, is also known to inhibit the migration of macrophages. However,
it must be acknowledged that the role of MIF in macrophage inhibition is still controversial. In
addition, a humanized niche model of the osteosarcoma graft that provided us with additional
information on the osteosarcoma development in the context of CI targeting and establishes
a more disease-relevant environment for tumor growth measurement, also presented with a
increased macrophage infiltrations and downregulation of the HIF1-MIF axis in the 143B-/-
tumors. Taken together, the abnormal vessels indicative of myeloid-driven vasculogenesis,
the invasion of macrophages found in CI-deficient tumors and the reduction of their number
when HIF-1 activity was complemented by TM-HIF-1α and a similar phenomenon of higher
macrophages and decreased HIF1-MIF axis presented in the orthotopic 143B-/- tumors, all
together suggest that macrophage abundance is an implication of HIF-1α destabilization in
143B-/- tumors.
On the other hand, analysis of HCT-/-HIF-TM and HCT-/-Mock revealed that the macrophage
count was unchanged in them. Furthermore, although qRT-PCR displayed a decrease in the
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MIF expression in HCT-/- xenografts at day 10, its gene expression 30 days in vivo and also
in vitro in hypoxia and intracellular protein expression of xenografts showed no difference
in MIF expression between the HCT-/- and HCT+/+ tumors. Moreover, HCT-/-HIF-TM and
HCT-/-Mock masses also showed no difference in the MIF expression both in vitro and in vivo
indicating that the MIF-HIF1 axis was not responsible for macrophage attraction in these mod-
els. Furthermore we hypothesized that MIF down regulation could depend on p53 since HCT
models lacked their expression. A strong correlation between inflammation and tumourigenesis
is demonstrated by MIF. As well as its proven function in inflammation, by inhibiting p53
aggregation, MIF directly promotes tumourigenesis (Vogelstein et al., 2000; Lu et al., 2007).
p53 is a classic tumour suppressor gene that can stimulate cell cycle arrest and apoptosis in
response to DNA damage. This essential checkpoint for preserving genetic stability interferes
with the absence or downregulation of p53 and enables cell survival and proliferation despite
possible mutation accumulation. Functional screens conducted by Hudson et al. identified MIF
as one of the cDNAs capable of negatively regulating p53 (Hudson et al., 1999). Additionally,
it is also shown that in a p53-dependent manner, MIF controls HIF-1 activity (Oda et al., 2008).
Therefore, we hypothesized that MIF regulation could depend on p53 since HCT models lacked
the expression of this tumor suppressor. It must be acknowledged that when it comes to p53,
there is a massive amount of accumulated literature and the list of proteins that interact with
p53 is broad. Furthermore, p53 and MIF display multifaceted functions and it is therefore
difficult to rationalize in our models with just mRNA and intracellular MIF and p53 expressions,
what is their exact link. However, in the context of the data we have, we can suggest that the
addition of WT p53 or Mut p53 upregulates MIF expression in HCT-/- tumors in hypoxia when
compared to the HCT-/- p53 null tumors. In conclusion the lack of downregulation of MIF in
HCT-/- cells does not depend on p53 expression.
For the preparation and export of proteins to the extracellular environment, the protein
secretory pathway is essential, effective and precise molecular machinery (Feizi et al., 2017).
We reasoned that tissue-specific expression of secretome could put different post-translational
modifications processing pressure on secretory pathway subsystems, which could possibly
explain the contradictory results of MIF expression between 143B and HCT models. In
this context, we can suggest that although the macrophage data revealed a more generic
redistribution of TME in CI-deficient tumors, the mechanism behind their recruitment maybe
exclusive and tissue specific. This result further emphasizes the fact that the sensitivity of
tissues to particular oncogenic events varies greatly and that barriers to tumour development
are highly tissue-specific. Unraveling processes that control their tissue-specific manifestations
are crucial to our knowledge of the etiologies of diseases and may lead efforts to establish
treatments. The heterogeneous populations in a tumor including the TME secrete multiple
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signals that, individually and collectively, can promote or impede any or all of the hallmarks of
cancer necessary for tumor growth, development, and progression. In this context, the other
cytokines analyzed by the cytokine array, are suggested to have a paradoxical pro-tumorgenic
and anti-tumorgenic effect on cancer cells. IL-8 secreted by the macrophages of TME promoted
tumor migration and survival (Fu et al., 2015). CXCL1 secreted by TAMs promoted breast
cancer metastasis via NF-κB/SOX4 activation (Wang et al., 2018). Interestingly, both these
cytokines promoted EMT process. Therefore the upregulation of the 1L-8 and CXCL1 could
possibly be attributed to the higher macrophage abundance and in turn their secretion in our
143B-/- tumors. Cytokines CXCL12, SERPIN-E1 and G-CSF are known to be induced in
hypoxia by HIF-1α (Ceradini et al., 2004; D’Alessandro et al., 2019; Chafe et al., 2015)
and are also inhibited by metformin treatment (Dirat et al., 2015; Kita et al., 2012; Kim et
al., 2017) which could possibly explain their downregulation in 143B-/- tumors since they
rarely acquire hypoxic phenotype due to unstable HIF-1α . Therefore, future research should
explore the effects of these cytokines on our models to gain further experimental evidence.
In addition, it would also be interesting to check if the above cytokines were tumor or TME
derived. Apart from the possibility of tissue-specific TAM attraction, another hypothesis
may be that MIF downregulation is merely a consequence of HIF-1 inactivation, and that
TAM abundance in CI deficient tumors is guided by another factor, possibly common to both
HCT and 143B models. With the aim of understanding whether such a common factor exists,
proteomics and metabolomics has been performed on the secretome of the CI deficient and
CI competent xenografts. However, proteomics did not identify any common factors between
143B and HCT, and some of them showed to have opposite expression levels in the two models.
Among the proteins identified, secreted protein acidic and rich in cysteine (SPARC), that binds
calcium in the bone, was found to be upregulated in the 143B-/- but downregulated in the
HCT-/-. The multifaceted effects of SPARC is due to its involvement in numerous biological
functions like, modulation of cell-extracellular matrix (ECM) interaction, angiogenesis and
tissue remodeling (Kzhyshkowska et al., 2006; Gilles et al., 1998). Interestingly it is one
of the factors that drive macrophage-mediated tumor invasion (Sangaletti et al., 2008). On
the other, SPARC derived from M2 macrophage phenotype attenuated its proliferative effects
in gastric cancer (Hu et al., 2020). The complexity of SPARC effects emanates from the
cell origin and the interplay between its production by tumor and TME, which explains the
contradictory results in 143B and HCT CI deficient tumors. In order to completely interpret and
understand the proteomics data, its needs to be further analyzed using GO- term enrichment
analysis. Metabolomics plays a vital role in dissecting the possible biochemical rearrangements
in cancer cells. As mentioned before, intratumoral mechanisms of metabolite communication
function symbiotically to promote repair, and development of tumors, or competitively to
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inhibit immunity to antitumors. For example, succinate induces intracellular calcium in
DCs, facilitating migratory responses and working synergistically inducing pro-inflammatory
production of cytokines with Toll-like receptor ligands. Succinate effectively enhanced antigen
specific activation of T cells via SUCNR1 (Rubic et al., 2008). Similarly, itaconate a redirected
derivative from the TCA cycle was recently discovered to have a compelling immune-regulated
function. In LPS-treated murine bone marrow-derived macrophages (BMDMs) under dimethyl
itaconate (DI) administration activity of M1 macrophages has been reported to be partially
inhibited in vitro along with reduction of proinflammatory mediators like IL-1β and IL-
6 (Lampropoulou et al., 2016). IL-2-driven differentiation of CD4 + and CD8 + T cells
has been shown to be promoted by α-KG. H3K27me3 and DNA methylation states were
decreased by α-KG, establishing its function as a cofactor for DNA and histone demethylases
in T cells (Chisolm et al., 2017). In line with this, we identified 9 secreted metabolites
namely lactate, 2HG, Fumarate, Malate, α-KG, Glutamate, Alanine, KIC and KMV that
were accumulated, significantly more in CI deficient conditioned media of HCT and 143B
tumors. Previously identified with bioenergetics or biosynthesis, metabolites have arisen as
molecules of immune effectors with specific function of immune system regulation. They
act as signalling molecules linked to transcription factors, can alter the structure and function
of proteins, and can change the mechanisms of molecular and cellular signalling (Zaslona
and O’Neill, 2020). Interestingly most of the above mentioned metabolites have an effect
on macrophage polarization, proliferation or differentiation, which makes them a promising
target. Indeed, by inhibiting KDM5 histone demethylases fumarate incorporates immune
and metabolic circuits to cause macrophage epigenetic reprogramming (Arts et al., 2016).
Likewise, intracellular glutamate elevation and mGluR5 expression may induce metabolic
rearrangement in macrophages that may lead to the production of an immunosuppressive
phenotype (Shanshiashvili et al., 2017). Of note, since the release of extracellular glutamate has
been shown to allow tumor expansion and providing growth advantage in OXPHOS competent
tumors (Takano et al., 2001), its accumulation in CI deficient cells was unexpected.
Future studies are necessary to explore the role of each of these metabolites on macrophage
proliferation, migration, phagocytic activity, differentiation and polarization, for example in
co-culture experiments.
Finally, following the metabolomics, pathway analysis and metabolite set enrichment
analysis was carried out, which could be proposed as a future research avenue. It is well
known that cancer cells often use other amino acids as "alternative fuels" to compete with
different cells in the tumor stroma for energy and to maximize the use of nutrients during tumor
evolution either by metabolic competition or through the process of macropinocytosis (Keenan
et al., 2015). The majority of carbon in cancer cells originates from amino acids, which, in the
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case of certain non-essential amino acids, are either taken up directly from the environment or
synthesized de novo. For example, the study by Nilsson and co showed that when produced in
the mitochondria, glutamate is metabolized but excreted when produced in abundance in the
cytosol (Nilsson et al., 2020). Our metabolite enrichment and pathway analysis suggests the
amino acid metabolism in addition to glycolysis was differentially regulated in our CI deficient
and CI competent models and thus lead us to speculate that metabolic changes induced in
cancer cells upon CI deficiency could triggers them to utilize the amino acid released by the
tumor stroma for their survival as described in a review by Vettore et al., 2020. Moreover,
the deregulated uptake of amino acids is another frequently found metabolic perturbation in
cancer cells (Yang et al., 2017). However, this needs to be validated with metabolic tracing
experiments. In conclusion, further insight into metabolic dependencies can be provided by
fully understanding the metabolic flexibility and diversity of the use of amino acids in cancer
cells. The additional degree of sophistication provided to and altered by TME populations in
response to metabolic therapy draws attention to the fact that even the most general treatment
may involve customized adjuvant therapies targeting TME. Therefore, in order to guide such
therapeutic choices, a comprehensive pre-evaluation of the immunophenotype and stromal
proportion of a tumor should be considered.
Chapter 6
CONCLUSIONS
Despite a broad knowledge of metabolic regulation based on nearly a century of biochemistry
studies, our knowledge of how pathways are regulated to promote cell proliferation remains
incomplete. In a hypoxic tumor microenvironment, tumor cells also have the potential to adjust
their metabolism and prefer metabolic pathways that are less oxygen dependent to satisfy
their demand for energy. Keeping in mind the importance of the hypoxic adaption in cancer
cells, our study proves that CI deficient 143B and HCT tumors display a reduced HIF-1α
stabilization phenotype that accounts for their anti-tumorigenic potential in various in vitro
and in vivo settings. By activating non-cell-autonomous pathways, independent of HIF-1α , CI-
deficient tumors guarantee nutritional availability and indeed, we show decreased tumor growth
accompanied by downregulation of MIF (only in the case of osteosarcomas) and excess of
TAM in CI deficient models, indicating that it may be one of the adaptive mechanisms enabled
to maintain survival after CI targeting. In addition it is well known that hypoxia-mediated
tumour-secreted proteins play a multi-directional role within TME, which probed us to identify
a common HIF-1α independent mechanism of macrophage attraction among the two cell types
within the altered secretion profile of CI deficient tumors for a more specific inhibition using
the omics approach. Our results on the metabolomics analysis of the CI deficient secretome
identified accumulation of lactate, fumarate, malate, 2-HG, BCKA’s (KIC, KMV), glutamate,
αKG and alanine that could possibly explain the TAM accumulation phenotype in these tumors.
This was not surprising since in ETC impairment conditions, NADH accumulates and inhibits
all regulatory enzymes in the TCA cycle, resulting in the shutdown of the TCA cycle and
accumulation of its intermediates. However, the effects and molecular mechanism of action
of these intermediates in immunoregulation, more specifically in the context of mitochondrial
respiration deficiency and macrophages has yet to be investigated. In conclusion, our results
provide a novel insight into the alternative survival mechanisms adapted by the slow growing
but persistent CI deficient tumors and identifies potential mode of mechanisms of the TAM
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recruitment in them. High expression of immune control point proteins in TME promotes
metabolic reprogramming in the microenvironment of the tumor, further creating a positive
feedback loop to sustain or worsen their growth. Combinational therapy targeting metabolism
and immunity may be helpful in this aspect. In line with this, our results also highlights the
importance of considering tumor type and their environmental context for determining the
potential efficacy of any adjuvant therapies targeting cancer metabolism and TME.
Chapter 7
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